1
|
Blay JY, Penel N, Valentin T, Anract P, Duffaud F, Dufresne A, Verret B, Cordoba A, Italiano A, Brahmi M, Henon C, Amouyel T, Ray-Coquard I, Ferron G, Boudou-Rouquette P, Tlemsani C, Salas S, Rochwerger R, Faron M, Bompas E, Ducassou A, Gangloff D, Gouin F, Firmin N, Piperno-Neumann S, Rios M, Ropars M, Kurtz JE, Le Nail LR, Bertucci F, Carrere S, Llacer C, Watson S, Bonvalot S, Leroux A, Perrin C, Gantzer J, Pracht M, Narciso B, Monneur A, Lebbe C, Hervieu A, Saada-Bouzid E, Dubray-Longeras P, Fiorenza F, Chaigneau L, Nevieres ZM, Soibinet P, Bouché O, Guillemet C, Spano JP, Ruzic JC, Isambert N, Vaz G, Meeus P, Karanian M, Ngo C, Coindre JM, De Pinieux G, Le Loarer F, Ducimetiere F, Chemin C, Morelle M, Toulmonde M, Le Cesne A. Improved nationwide survival of sarcoma patients with a network of reference centers. Ann Oncol 2024; 35:351-363. [PMID: 38246351 DOI: 10.1016/j.annonc.2024.01.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2023] [Revised: 01/03/2024] [Accepted: 01/04/2024] [Indexed: 01/23/2024] Open
Abstract
BACKGROUND We investigated the impact of the implementation of a network of reference centers for sarcomas (NETSARC) on the care and survival of sarcoma patients in France since 2010. PATIENTS AND METHODS NETSARC (netsarc.org) is a network of 26 reference sarcoma centers with specialized multidisciplinary tumor boards (MDTBs), funded by the French National Cancer Institute (INCa) since 2010. Its aims are to improve the quality of diagnosis and care of sarcoma patients. Patients' characteristics, treatments, and outcomes are collected in a nationwide database. The objective of this analysis was to compare the survival of patients in three periods: 2010-2012 (non-exhaustive), 2013-2015, and 2016-2020. RESULTS A total of 43 975 patients with sarcomas, gastrointestinal stromal tumors (GISTs), or connective tissue tumors of intermediate malignancy were included in the NETSARC+ database since 2010 (n = 9266 before 2013, n = 12 274 between 2013 and 2015, n = 22 435 in 2016-2020). Median age was 56 years, 50.5% were women, and 13.2% had metastasis at diagnosis. Overall survival was significantly superior in the period 2016-2020 versus 2013-2015 versus 2010-2012 for the entire population, for patients >18 years of age, and for both metastatic and non-metastatic patients in univariate and multivariate analyses (P < 0.0001). Over the three periods, we observed a significantly improved compliance to clinical practice guidelines (CPGs) nationwide: the proportion of patients biopsied before surgery increased from 62.9% to 72.6%; the percentage of patients presented to NETSARC MDTBs before first surgery increased from 31.7% to 44.4% (P < 0.0001). The proportion of patients with R0 resection on first surgery increased (from 36.1% to 46.6%), while R2 resection rate decreased (from 10.9% to 7.9%), with a better compliance and improvement in NETSARC centers. CONCLUSIONS The implementation of the national reference network for sarcoma was associated with an improvement of overall survival and compliance to guidelines nationwide in sarcoma patients. Referral to expert networks for sarcoma patients should be encouraged, though a better compliance to CPGs can still be achieved.
Collapse
Affiliation(s)
- J Y Blay
- Department of Medical Oncology, Centre Léon Bérard & Université Claude Bernard, Lyon; Department of Surgical Oncology, Centre Léon Bérard & Université Claude Bernard, Lyon.
| | - N Penel
- Department of Medical Oncology, Centre Oscar Lambret, Lille
| | - T Valentin
- Department of Medical Oncology, Institut Claudius Regaud & IUCT Oncopole Toulouse, Toulouse
| | - P Anract
- Department of Orthopedics, Hôpital Cochin Saint Vincent de Paul, Paris
| | - F Duffaud
- Department of Medical Oncology, La Timone University Hospital, Marseille
| | - A Dufresne
- Department of Medical Oncology, Centre Léon Bérard & Université Claude Bernard, Lyon; Department of Surgical Oncology, Centre Léon Bérard & Université Claude Bernard, Lyon
| | - B Verret
- Department of Medicine, Gustave Roussy Cancer Campus, Villejuif; Department of Surgery, Gustave Roussy Cancer Campus, Villejuif
| | - A Cordoba
- Department of Medical Oncology, Centre Oscar Lambret, Lille
| | - A Italiano
- Department of Medical Oncology, Institut Bergonié, Bordeaux; Department of Surgical Oncology, Institut Bergonié, Bordeaux
| | - M Brahmi
- Department of Medical Oncology, Centre Léon Bérard & Université Claude Bernard, Lyon; Department of Surgical Oncology, Centre Léon Bérard & Université Claude Bernard, Lyon
| | - C Henon
- Department of Medicine, Gustave Roussy Cancer Campus, Villejuif; Department of Surgery, Gustave Roussy Cancer Campus, Villejuif
| | - T Amouyel
- Department of Medical Oncology, Centre Oscar Lambret, Lille
| | - I Ray-Coquard
- Department of Medical Oncology, Centre Léon Bérard & Université Claude Bernard, Lyon; Department of Surgical Oncology, Centre Léon Bérard & Université Claude Bernard, Lyon
| | - G Ferron
- Department of Medical Oncology, Institut Claudius Regaud & IUCT Oncopole Toulouse, Toulouse
| | | | - C Tlemsani
- Department of Orthopedics, Hôpital Cochin Saint Vincent de Paul, Paris
| | - S Salas
- Department of Medical Oncology, La Timone University Hospital, Marseille
| | - R Rochwerger
- Department of Medical Oncology, La Timone University Hospital, Marseille
| | - M Faron
- Department of Medicine, Gustave Roussy Cancer Campus, Villejuif; Department of Surgery, Gustave Roussy Cancer Campus, Villejuif
| | - E Bompas
- Department of Medical Oncology, Cochin Hospital, Paris; Department of Medical Oncology, Centre René Gauducheau, Nantes St. Herblain
| | - A Ducassou
- Department of Medical Oncology, Institut Claudius Regaud & IUCT Oncopole Toulouse, Toulouse
| | - D Gangloff
- Department of Medical Oncology, Institut Claudius Regaud & IUCT Oncopole Toulouse, Toulouse
| | - F Gouin
- Department of Medical Oncology, Centre Léon Bérard & Université Claude Bernard, Lyon; Department of Surgical Oncology, Centre Léon Bérard & Université Claude Bernard, Lyon; Service Orthopedie, CHU Nantes, Nantes
| | - N Firmin
- Department of Medical & Surgical & Radiotherapy Oncology ICM, Montpellier
| | - S Piperno-Neumann
- INSERM U1194, IRCM, Univ Montpellier, Montpellier; Department of Medical Oncology, Institut Curie, Paris; Department of Surgical Oncology, Institut Curie, Paris
| | - M Rios
- Department of Medical Oncology, Centre Alexis Vautrin, Vandoeuvre-lès-Nancy
| | - M Ropars
- Department of Orthopedics, CHU Rennes, Rennes
| | | | | | - F Bertucci
- Department of Medical Oncology, Institut Paoli-Calmettes, Marseille
| | - S Carrere
- Service Orthopedie, CHU Nantes, Nantes
| | - C Llacer
- Service Orthopedie, CHU Nantes, Nantes
| | - S Watson
- Department of Medical & Surgical & Radiotherapy Oncology ICM, Montpellier
| | - S Bonvalot
- Department of Medical & Surgical & Radiotherapy Oncology ICM, Montpellier
| | - A Leroux
- INSERM U1194, IRCM, Univ Montpellier, Montpellier
| | - C Perrin
- Department of Medical Oncology, Eugene Marquis Comprehensive Cancer Center, Rennes
| | - J Gantzer
- Department of Medical Oncology, Centre Alexis Vautrin, Vandoeuvre-lès-Nancy
| | - M Pracht
- Department of Medical Oncology, Eugene Marquis Comprehensive Cancer Center, Rennes
| | - B Narciso
- Department of Orthopedic Surgery, Tours
| | - A Monneur
- Department of Medical Oncology, Institut Paoli-Calmettes, Marseille
| | - C Lebbe
- Department of Dermatology, INSERM U976 University Paris Diderot Saint Louis Hospital, Paris; Department of CIC, INSERM U976 University Paris Diderot Saint Louis Hospital, Paris
| | - A Hervieu
- Department of Medical Oncology, Centre Georges François Leclerc, Dijon
| | - E Saada-Bouzid
- Department of Medical Oncology, Centre Antoine-Lacassagne, Nice
| | - P Dubray-Longeras
- Department of Medical Oncology, Centre Jean Perrin, Clermont-Ferrand
| | - F Fiorenza
- Department of Orthopedic Surgery, CHU Limoges, Limoges
| | - L Chaigneau
- Department of Medicine, CHU Besancon, Besancon
| | | | - P Soibinet
- Department of Medicine, Centre Francois Baclesse, Caen
| | - O Bouché
- Department of Gastroenterology, CHU Reims, Reims
| | - C Guillemet
- Department of Medical Oncology, Centre J Godinot Reims, Reims
| | - J P Spano
- Department of Oncology, Hôpital Pitié-Salpétriere, Paris
| | - J C Ruzic
- Departement d'oncologie, CHU, La Reunion
| | - N Isambert
- Service d'oncologie, CHU Poitiers, Poitiers, France
| | - G Vaz
- Department of Medical Oncology, Centre Léon Bérard & Université Claude Bernard, Lyon; Department of Surgical Oncology, Centre Léon Bérard & Université Claude Bernard, Lyon
| | - P Meeus
- Department of Medical Oncology, Centre Léon Bérard & Université Claude Bernard, Lyon; Department of Surgical Oncology, Centre Léon Bérard & Université Claude Bernard, Lyon
| | - M Karanian
- Department of Medical Oncology, Centre Léon Bérard & Université Claude Bernard, Lyon; Department of Surgical Oncology, Centre Léon Bérard & Université Claude Bernard, Lyon
| | - C Ngo
- Department of Medicine, Gustave Roussy Cancer Campus, Villejuif; Department of Surgery, Gustave Roussy Cancer Campus, Villejuif
| | - J M Coindre
- Department of Medical Oncology, Institut Bergonié, Bordeaux; Department of Surgical Oncology, Institut Bergonié, Bordeaux
| | | | - F Le Loarer
- Department of Medical Oncology, Institut Bergonié, Bordeaux; Department of Surgical Oncology, Institut Bergonié, Bordeaux
| | - F Ducimetiere
- Department of Medical Oncology, Centre Léon Bérard & Université Claude Bernard, Lyon; Department of Surgical Oncology, Centre Léon Bérard & Université Claude Bernard, Lyon
| | - C Chemin
- Department of Medical Oncology, Centre Léon Bérard & Université Claude Bernard, Lyon; Department of Surgical Oncology, Centre Léon Bérard & Université Claude Bernard, Lyon
| | - M Morelle
- Department of Medical Oncology, Centre Léon Bérard & Université Claude Bernard, Lyon; Department of Surgical Oncology, Centre Léon Bérard & Université Claude Bernard, Lyon
| | - M Toulmonde
- Department of Medical Oncology, Institut Bergonié, Bordeaux; Department of Surgical Oncology, Institut Bergonié, Bordeaux
| | - A Le Cesne
- Department of Medicine, Gustave Roussy Cancer Campus, Villejuif; Department of Surgery, Gustave Roussy Cancer Campus, Villejuif
| |
Collapse
|
2
|
Blay JY, Tlemsani C, Toulmonde M, Italiano A, Rios M, Bompas E, Valentin T, Duffaud F, Le Nail LR, Watson S, Firmin N, Dubray-Longeras P, Ropars M, Perrin C, Hervieu A, Lebbe C, Saada-Bouzid E, Soibinet P, Fiorenza F, Bertucci F, Boudou P, Vaz G, Bonvalot S, Honoré C, Marec-Berard P, Minard V, Cleirec M, Biau D, Meeus P, Babinet A, Dumaine V, Carriere S, Fau M, Decanter G, Gouin F, Ngo C, Le Loarer F, Karanian M, Meurgey A, Dufresne A, Brahmi M, Chemin-Airiau C, Ducimetiere F, Penel N, Le Cesne A. Sclerosing Epithelioid Fibrosarcoma (SEF) versus Low Grade Fibromyxoid Sarcoma (LGFMS): Presentation and outcome in the nationwide NETSARC+ series of 330 patients over 13 years. Eur J Cancer 2024; 196:113454. [PMID: 38008029 DOI: 10.1016/j.ejca.2023.113454] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2023] [Accepted: 11/08/2023] [Indexed: 11/28/2023]
Abstract
Sclerosing Epithelioid Fibrosarcoma (SEF) and Low Grade Fibromyxoid Sarcoma (LGFMS) are ultrarare sarcomas sharing common translocations whose natural history are not well known. We report on the nationwide exhaustive series of 330 patients with SEF or LGFMS in NETSARC+ since 2010. PATIENTS AND METHODS NETSARC (netsarc.org) is a network of 26 reference sarcoma centers with specialized multidisciplinary tumor boards (MDTB). Since 2010, (i) pathological review has been mandatory for sarcoma,and (ii) tumour/patients' characteristics have been collected in the NETSARC+ nationwide database. The characteristics of patients with SEF and LGFMS and their outcome are compared. RESULTS 35/73 (48%) and 125/257(49%) of patients with SEF and LGFMS were female. More visceral, bone and trunk primary sites were observed in SEF (p < 0.001). 30% of SEF vs 4% of LGFMS patients had metastasis at diagnosis (p < 0.0001). Median size of the primary tumor was 51 mm (range 10-90) for LGFMS vs 80 (20-320) for SEF (p < 0.001). Median age for LGFMS patients was 12 years younger than that of SEF patients (43 [range 4-98] vs 55 [range 10-91], p < 0.001). Neoadjuvant treatment was more often given to SEF (16% vs 9%, p = 0.05). More patients with LGFMS were operated first in reference centers (51% vs 26%, p < 0.001). The R0 rate on the operative specimen was 41% in LGFMS vs 16% in SEF (p < 0.001). Median event-free survival (EFS) of patients with SEF and LGFMS were 32 vs 136 months (p < 0.0001). The median overall survival (OS) was not reached. Fifty-months OS was 93% vs 81% for LGFMS vs SEF (p = 0.05). Median OS was 77 months after first relapse, similar for SEF and LGFMS. In multivariate analysis, age, tumor size, metastasis at diagnosis were independent prognostic factors for OS in LGFMS. CONCLUSIONS Although sharing close molecular alterations, SEF and LGFMS have a different natural history, clinical presentation and outcome, with a higher risk of metastatic relapse in SEF. Survival after relapse is longer than with other sarcomas, and similar for SEF and LGFMS.
Collapse
Affiliation(s)
- J Y Blay
- Centre Léon Bérard & Université Claude Bernard, Lyon, France.
| | | | - M Toulmonde
- Departement of Medical Oncology, Institut Bergonié, Bordeaux, France
| | - A Italiano
- Departement of Medical Oncology, Institut Bergonié, Bordeaux, France
| | - M Rios
- Institut Cancerologie Lorraine, Centre Alexis Vautrin, Nancy, France
| | - E Bompas
- Department of Medical Oncology, Institut de Cancerologie Ouest Nantes, France
| | - T Valentin
- Institut Claudius Regaud & Institut Universitaire de Cancerologie, Oncopole, Toulouse, France
| | - F Duffaud
- La Timone University Hospital, Marseille, France
| | | | - S Watson
- Dept of Medical Oncology, Institut Curie & INSERM U830, Institut Curie Research Center, Paris, France
| | - N Firmin
- Institut de Cancérologie de Montpellier, Montpellier, France
| | | | - M Ropars
- Eugene Marquis Comprehensive Cancer Center, France
| | | | - A Hervieu
- Centre George Francois Leclerc, Dijon, France
| | - C Lebbe
- Centre Georges François Leclerc, Dijon, France
| | - E Saada-Bouzid
- Dermato-Oncology Unit, Saint Louis Hospital, Paris, France
| | | | | | - F Bertucci
- Institut Paoli-Calmettes, Marseille, France
| | | | - G Vaz
- Centre Léon Bérard & Université Claude Bernard, Lyon, France
| | | | - C Honoré
- Gustave Roussy Cancer Campus, Villejuif, France
| | - P Marec-Berard
- Centre Léon Bérard & Université Claude Bernard, Lyon, France
| | - V Minard
- Gustave Roussy Cancer Campus, Villejuif, France
| | | | - D Biau
- Hopital Cochin, Paris, France
| | - P Meeus
- Centre Léon Bérard & Université Claude Bernard, Lyon, France
| | | | | | - S Carriere
- Institut de Cancérologie de Montpellier, Montpellier, France
| | - M Fau
- Departement of Medical Oncology, Institut Bergonié, Bordeaux, France
| | - G Decanter
- Univ. Lille, CHU Lille, ULR 2694 - Metrics: Evaluation des technologies de santé et des pratiques médicales, F-59000 Lille, France; Department of Medical Oncology, Centre Oscar Lambret, Lille, France
| | - F Gouin
- Centre Léon Bérard & Université Claude Bernard, Lyon, France
| | - C Ngo
- Departement of Medical Oncology, Institut Bergonié, Bordeaux, France
| | | | - M Karanian
- Centre Léon Bérard & Université Claude Bernard, Lyon, France
| | - A Meurgey
- Centre Léon Bérard & Université Claude Bernard, Lyon, France
| | - A Dufresne
- Centre Léon Bérard & Université Claude Bernard, Lyon, France
| | - M Brahmi
- Centre Léon Bérard & Université Claude Bernard, Lyon, France
| | - C Chemin-Airiau
- Centre Léon Bérard & Université Claude Bernard, Lyon, France
| | - F Ducimetiere
- Centre Léon Bérard & Université Claude Bernard, Lyon, France.
| | - N Penel
- Univ. Lille, CHU Lille, ULR 2694 - Metrics: Evaluation des technologies de santé et des pratiques médicales, F-59000 Lille, France; Department of Medical Oncology, Centre Oscar Lambret, Lille, France
| | | |
Collapse
|
3
|
Blay JY, Piperno-Neumann S, Watson S, Dufresne A, Valentin T, Duffaud F, Toulmonde M, Italiano A, Bertucci F, Tlemsani C, Firmin N, Bompas E, Perrin C, Ropars M, Saada-Bouzid E, Dubray-Longeras P, Hervieu A, Lebbe C, Gantzer J, Chaigneau L, Fiorenza F, Rios M, Isambert N, Soibinet P, Boudou-Roquette P, Verret B, Ferron G, Ryckewaert T, Lebellec L, Brahmi M, Gouin F, Meeus P, Vaz G, Le Loarer F, Karanian M, De Pinieux G, Ducimetiere F, Chemin C, Morelle M, Le Cesne A, Penel N. Epithelioid hemangio-endothelioma (EHE) in NETSARC: The nationwide series of 267 patients over 12 years. Eur J Cancer 2023; 192:113262. [PMID: 37625241 DOI: 10.1016/j.ejca.2023.113262] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2023] [Revised: 07/07/2023] [Accepted: 07/24/2023] [Indexed: 08/27/2023]
Abstract
EPITHELIOID HEMANGIOENDOTHELIOMA A NATIONWIDE STUDY: Epithelioid hemangioendothelioma (EHE) is an ultrarare sarcoma whose natural history and treatment is not well defined. We report on the presentation and outcome of 267 patients with EHE in the NETSARC+ network since 2010 in France. PATIENTS AND METHODS NETSARC (netsarc.org) is a network of 26 reference sarcoma centres with specialised multidisciplinary tumour boards (MDTB), funded by the French National Cancer Institute (NCI), Institut National du Cancer (INCA). Since 2010, presentation to an MDTB and second pathological review are mandatory for sarcoma patients. Patients' characteristics are collected in a nationwide database regularly monitored with stable incidence since 2013. The characteristics of patients with EHE at diagnosis are presented as well as progression-free survival (PFS), overall survival (OS), and outcome under treatment. RESULTS Two hundred and sixty-seven patients with EHE were included in the NETSARC+ database since 2010. Median age in the series was 51 (range 10-90) years, 58% were women. Median tumour size was 37 mm (4-220). Forty-eight percent, 42%, and 10% were visceral, soft parts, or bone primaries. The most frequent sites were liver (28%), lung (13%). 40% were reported to have systemic (i.e. multifocal or metastatic disease) at diagnosis. With a median follow-up of 20 months, OS and PFS rates at 24 months were 82% and 67%, with 10-year projected OS and PFS of 62% and 21% respectively. Male and M+ patients at diagnosis had a significantly worse OS, but not PFS. Local treatment was associated with a favourable survival in localised but not in patients with advanced stage at diagnosis. For 23 patients receiving medical treatment, PFS and OS were 50.2% and 33.2% at 60 months were respectively. CONCLUSIONS EHE is a frequently metastatic sarcoma at diagnosis with a unique natural history. This study shows in a nationwide series over 12 years that most patients progressed but are still alive at 10 years, both in localised and metastatic stages.
Collapse
Affiliation(s)
- J Y Blay
- Department of Medical oncology, Centre Léon Bérard and Université Claude Bernard, Lyon, France.
| | - S Piperno-Neumann
- Department of Medical Oncology, Institut Curie and INSERM U830, Institut Curie Research Center, Paris, France
| | - S Watson
- Department of Medical Oncology, Institut Curie and INSERM U830, Institut Curie Research Center, Paris, France
| | - A Dufresne
- Department of Medical oncology, Centre Léon Bérard and Université Claude Bernard, Lyon, France
| | - T Valentin
- Department of Medical oncology, Institut Claudius Regaud and Institut Universitaire de Cancerologie, Oncopole, Toulouse, France
| | - F Duffaud
- Department of Medical oncology, La Timone University Hospital, Marseille, France
| | - M Toulmonde
- Departement of Medical Oncology, Institut Bergonié, Bordeaux, France
| | - A Italiano
- Departement of Medical Oncology, Institut Bergonié, Bordeaux, France
| | - F Bertucci
- Department of Medical oncology, Institut Paoli-Calmettes, Marseille, France
| | - C Tlemsani
- Department of Medical oncology, Hôpital Cochin-Saint-Vincent de Paul, Paris, France
| | - N Firmin
- Department of Medical oncology, Institut de Cancérologie de Montpellier, Montpellier, France
| | - E Bompas
- Department of Medical Oncology, Institut de Cancerologie Ouest, Nantes, France
| | - C Perrin
- Department of Medical oncology, Eugene Marquis Comprehensive Cancer Center and CHU, Rennes, France
| | - M Ropars
- Department of Medical oncology, Eugene Marquis Comprehensive Cancer Center and CHU, Rennes, France
| | - E Saada-Bouzid
- Department of Medical oncology, Centre Antoine-Lacassagne, Nice, France
| | - P Dubray-Longeras
- Department of Medical oncology, Centre Georges François Leclerc, Dijon, France
| | - A Hervieu
- Department of Medical oncology, Centre Jean Perrin/ERTICa EA 4677, Clermont-Ferrand, France
| | - C Lebbe
- Department of Medical oncology, Oncology Unit, Saint Louis Hospital, Paris, France
| | - J Gantzer
- Department of Medicine, ICANS, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - L Chaigneau
- Department of Medical oncology, CHU Besancon, Besançon, France
| | - F Fiorenza
- Department of Medical oncology, CHU Limoges, Limoges, France
| | - M Rios
- Department of Medical oncology, Institut Cancerologie Lorraine, Centre Alexis Vautrin, Nancy, France
| | - N Isambert
- Department of Medical oncology, CHU, Poitiers, France
| | - P Soibinet
- Department of Medical oncology, Institut J Godinot Reims, Reims, France
| | - P Boudou-Roquette
- Department of Medical oncology, Hôpital Cochin-Saint-Vincent de Paul, Paris, France
| | - B Verret
- Department of Medical oncology, Gustave Roussy Cancer Campus, Villejuif, France
| | - G Ferron
- Department of Medical oncology, Institut Claudius Regaud and Institut Universitaire de Cancerologie, Oncopole, Toulouse, France
| | - T Ryckewaert
- Department of Medical oncology, Centre Oscar Lambret, and Université de Lille ULR 2694, Lille, France
| | - L Lebellec
- Department of Medical oncology, Centre Oscar Lambret, and Université de Lille ULR 2694, Lille, France
| | - M Brahmi
- Department of Medical oncology, Centre Léon Bérard and Université Claude Bernard, Lyon, France
| | - F Gouin
- Department of Medical oncology, Centre Léon Bérard and Université Claude Bernard, Lyon, France
| | - P Meeus
- Department of Medical oncology, Centre Léon Bérard and Université Claude Bernard, Lyon, France
| | - G Vaz
- Department of Medical oncology, Centre Léon Bérard and Université Claude Bernard, Lyon, France
| | - F Le Loarer
- Departement of Medical Oncology, Institut Bergonié, Bordeaux, France
| | - M Karanian
- Department of Medical oncology, Centre Léon Bérard and Université Claude Bernard, Lyon, France
| | - G De Pinieux
- Department of Medical oncology, CHU Tours, Tours, France
| | - F Ducimetiere
- Department of Medical oncology, Centre Léon Bérard and Université Claude Bernard, Lyon, France
| | - C Chemin
- Department of Medical oncology, Centre Léon Bérard and Université Claude Bernard, Lyon, France
| | - M Morelle
- Department of Medical oncology, Centre Léon Bérard and Université Claude Bernard, Lyon, France
| | - A Le Cesne
- Department of Medical oncology, Gustave Roussy Cancer Campus, Villejuif, France
| | - N Penel
- Department of Medical oncology, Centre Oscar Lambret, and Université de Lille ULR 2694, Lille, France
| |
Collapse
|
4
|
Vagliano I, Dormosh N, Rios M, Luik TT, Buonocore TM, Elbers PWG, Dongelmans DA, Schut MC, Abu-Hanna A. Prognostic models of in-hospital mortality of intensive care patients using neural representation of unstructured text: A systematic review and critical appraisal. J Biomed Inform 2023; 146:104504. [PMID: 37742782 DOI: 10.1016/j.jbi.2023.104504] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2023] [Revised: 08/29/2023] [Accepted: 09/21/2023] [Indexed: 09/26/2023]
Abstract
OBJECTIVE To review and critically appraise published and preprint reports of prognostic models of in-hospital mortality of patients in the intensive-care unit (ICU) based on neural representations (embeddings) of clinical notes. METHODS PubMed and arXiv were searched up to August 1, 2022. At least two reviewers independently selected the studies that developed a prognostic model of in-hospital mortality of intensive-care patients using free-text represented as embeddings and extracted data using the CHARMS checklist. Risk of bias was assessed using PROBAST. Reporting on the model was assessed with the TRIPOD guideline. To assess the machine learning components that were used in the models, we present a new descriptive framework based on different techniques to represent text and provide predictions from text. The study protocol was registered in the PROSPERO database (CRD42022354602). RESULTS Eighteen studies out of 2,825 were included. All studies used the publicly-available MIMIC dataset. Context-independent word embeddings are widely used. Model discrimination was provided by all studies (AUROC 0.75-0.96), but measures of calibration were scarce. Seven studies used both structural clinical variables and notes. Model discrimination improved when adding clinical notes to variables. None of the models was externally validated and often a simple train/test split was used for internal validation. Our critical appraisal demonstrated a high risk of bias in all studies and concerns regarding their applicability in clinical practice. CONCLUSION All studies used a neural architecture for prediction and were based on one publicly available dataset. Clinical notes were reported to improve predictive performance when used in addition to only clinical variables. Most studies had methodological, reporting, and applicability issues. We recommend reporting both model discrimination and calibration, using additional data sources, and using more robust evaluation strategies, including prospective and external validation. Finally, sharing data and code is encouraged to improve study reproducibility.
Collapse
Affiliation(s)
- I Vagliano
- Dept. of Medical Informatics, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands; Amsterdam Public Health (APH), Amsterdam, the Netherlands.
| | - N Dormosh
- Dept. of Medical Informatics, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands; Amsterdam Public Health (APH), Amsterdam, the Netherlands
| | - M Rios
- Centre for Translation Studies, University of Vienna, Vienna, Austria. https://twitter.com/zhizhid
| | - T T Luik
- Amsterdam Public Health (APH), Amsterdam, the Netherlands; Dept. of Medical Biology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands
| | - T M Buonocore
- Dept. of Electrical, Computer and Biomedical Engineering, University of Pavia, Pavia, Italy
| | - P W G Elbers
- Amsterdam Public Health (APH), Amsterdam, the Netherlands; Dept. of Intensive Care Medicine, Center for Critical Care Computational Intelligence (C4I), Amsterdam Medical Data Science (AMDS), Amsterdam Institute for Infection and Immunity (AII), Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands. https://twitter.com/zhizhid
| | - D A Dongelmans
- Amsterdam Public Health (APH), Amsterdam, the Netherlands; National Intensive Care Evaluation (NICE) Foundation, Amsterdam, the Netherlands; Dept. of Intensive Care Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands
| | - M C Schut
- Dept. of Medical Informatics, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands; Amsterdam Public Health (APH), Amsterdam, the Netherlands; Dept. of Clinical Chemistry, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands
| | - A Abu-Hanna
- Dept. of Medical Informatics, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands; Amsterdam Public Health (APH), Amsterdam, the Netherlands
| |
Collapse
|
5
|
Albakry MF, Alkhatib I, Alonso D, Amaral DWP, Aralis T, Aramaki T, Arnquist IJ, Ataee Langroudy I, Azadbakht E, Banik S, Bathurst C, Bhattacharyya R, Brink PL, Bunker R, Cabrera B, Calkins R, Cameron RA, Cartaro C, Cerdeño DG, Chang YY, Chaudhuri M, Chen R, Chott N, Cooley J, Coombes H, Corbett J, Cushman P, Das S, De Brienne F, Rios M, Dharani S, di Vacri ML, Diamond MD, Elwan M, Fascione E, Figueroa-Feliciano E, Fink CW, Fouts K, Fritts M, Gerbier G, Germond R, Ghaith M, Golwala SR, Hall J, Harms SAS, Hassan N, Hines BA, Hong Z, Hoppe EW, Hsu L, Huber ME, Iyer V, Kashyap VKS, Kelsey MH, Kubik A, Kurinsky NA, Lee M, Litke M, Liu J, Liu Y, Loer B, Lopez Asamar E, Lukens P, MacFarlane DB, Mahapatra R, Mast N, Mayer AJ, Meyer Zu Theenhausen H, Michaud É, Michielin E, Mirabolfathi N, Mohanty B, Nebolsky B, Nelson J, Neog H, Novati V, Orrell JL, Osborne MD, Oser SM, Page WA, Pandey L, Pandey S, Partridge R, Pedreros DS, Perna L, Podviianiuk R, Ponce F, Poudel S, Pradeep A, Pyle M, Rau W, Reid E, Ren R, Reynolds T, Tanner E, Roberts A, Robinson AE, Saab T, Sadek D, Sadoulet B, Sahoo SP, Saikia I, Sander J, Sattari A, Schmidt B, Schnee RW, Scorza S, Serfass B, Poudel SS, Sincavage DJ, Sinervo P, Speaks Z, Street J, Sun H, Terry GD, Thasrawala FK, Toback D, Underwood R, Verma S, Villano AN, von Krosigk B, Watkins SL, Wen O, Williams Z, Wilson MJ, Winchell J, Wykoff K, Yellin S, Young BA, Yu TC, Zatschler B, Zatschler S, Zaytsev A, Zeolla A, Zhang E, Zheng L, Zheng Y, Zuniga A, An P, Barbeau PS, Hedges SC, Li L, Runge J. First Measurement of the Nuclear-Recoil Ionization Yield in Silicon at 100 eV. Phys Rev Lett 2023; 131:091801. [PMID: 37721818 DOI: 10.1103/physrevlett.131.091801] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/21/2023] [Revised: 07/07/2023] [Accepted: 07/26/2023] [Indexed: 09/20/2023]
Abstract
We measured the nuclear-recoil ionization yield in silicon with a cryogenic phonon-sensitive gram-scale detector. Neutrons from a monoenergetic beam scatter off of the silicon nuclei at angles corresponding to energy depositions from 4 keV down to 100 eV, the lowest energy probed so far. The results show no sign of an ionization production threshold above 100 eV. These results call for further investigation of the ionization yield theory and a comprehensive determination of the detector response function at energies below the keV scale.
Collapse
Affiliation(s)
- M F Albakry
- Department of Physics & Astronomy, University of British Columbia, Vancouver, British Columbia V6T 1Z1, Canada
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - I Alkhatib
- Department of Physics, University of Toronto, Toronto, Ontario M5S 1A7, Canada
| | - D Alonso
- Instituto de Física Teórica UAM/CSIC, Universidad Autónoma de Madrid, 28049 Madrid, Spain
- Instituto de Física Teórica UAM-CSIC, Campus de Cantoblanco, 28049 Madrid, Spain
| | - D W P Amaral
- Department of Physics, Durham University, Durham DH1 3LE, United Kingdom
| | - T Aralis
- Division of Physics, Mathematics, & Astronomy, California Institute of Technology, Pasadena, California 91125, USA
| | - T Aramaki
- Department of Physics, Northeastern University, 360 Huntington Avenue, Boston, Massachusetts 02115, USA
| | - I J Arnquist
- Pacific Northwest National Laboratory, Richland, Washington 99352, USA
| | - I Ataee Langroudy
- Department of Physics and Astronomy, and the Mitchell Institute for Fundamental Physics and Astronomy, Texas A&M University, College Station, Texas 77843, USA
| | - E Azadbakht
- Department of Physics and Astronomy, and the Mitchell Institute for Fundamental Physics and Astronomy, Texas A&M University, College Station, Texas 77843, USA
| | - S Banik
- School of Physical Sciences, National Institute of Science Education and Research, HBNI, Jatni - 752050, India
| | - C Bathurst
- Department of Physics, University of Florida, Gainesville, Florida 32611, USA
| | - R Bhattacharyya
- Department of Physics and Astronomy, and the Mitchell Institute for Fundamental Physics and Astronomy, Texas A&M University, College Station, Texas 77843, USA
| | - P L Brink
- SLAC National Accelerator Laboratory/Kavli Institute for Particle Astrophysics and Cosmology, Menlo Park, California 94025, USA
| | - R Bunker
- Pacific Northwest National Laboratory, Richland, Washington 99352, USA
| | - B Cabrera
- Department of Physics, Stanford University, Stanford, California 94305, USA
| | - R Calkins
- Department of Physics, Southern Methodist University, Dallas, Texas 75275, USA
| | - R A Cameron
- SLAC National Accelerator Laboratory/Kavli Institute for Particle Astrophysics and Cosmology, Menlo Park, California 94025, USA
| | - C Cartaro
- SLAC National Accelerator Laboratory/Kavli Institute for Particle Astrophysics and Cosmology, Menlo Park, California 94025, USA
| | - D G Cerdeño
- Instituto de Física Teórica UAM/CSIC, Universidad Autónoma de Madrid, 28049 Madrid, Spain
- Instituto de Física Teórica UAM-CSIC, Campus de Cantoblanco, 28049 Madrid, Spain
| | - Y-Y Chang
- Division of Physics, Mathematics, & Astronomy, California Institute of Technology, Pasadena, California 91125, USA
| | - M Chaudhuri
- School of Physical Sciences, National Institute of Science Education and Research, HBNI, Jatni - 752050, India
| | - R Chen
- Department of Physics & Astronomy, Northwestern University, Evanston, Illinois 60208-3112, USA
| | - N Chott
- Department of Physics, South Dakota School of Mines and Technology, Rapid City, South Dakota 57701, USA
| | - J Cooley
- Department of Physics, Southern Methodist University, Dallas, Texas 75275, USA
- SNOLAB, Creighton Mine #9, 1039 Regional Road 24, Sudbury, Ontario P3Y 1N2, Canada
| | - H Coombes
- Department of Physics, University of Florida, Gainesville, Florida 32611, USA
| | - J Corbett
- Department of Physics, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - P Cushman
- School of Physics & Astronomy, University of Minnesota, Minneapolis, Minnesota 55455, USA
| | - S Das
- School of Physical Sciences, National Institute of Science Education and Research, HBNI, Jatni - 752050, India
| | - F De Brienne
- Département de Physique, Université de Montréal, Montréal, Québec H3C 3J7, Canada
| | - M Rios
- Instituto de Física Teórica UAM/CSIC, Universidad Autónoma de Madrid, 28049 Madrid, Spain
- Instituto de Física Teórica UAM-CSIC, Campus de Cantoblanco, 28049 Madrid, Spain
| | - S Dharani
- Institute for Astroparticle Physics (IAP), Karlsruhe Institute of Technology (KIT), 76344 Eggenstein-Leopoldshafen, Germany
- Institut für Experimentalphysik, Universität Hamburg, 22761 Hamburg, Germany
| | - M L di Vacri
- Pacific Northwest National Laboratory, Richland, Washington 99352, USA
| | - M D Diamond
- Department of Physics, University of Toronto, Toronto, Ontario M5S 1A7, Canada
| | - M Elwan
- Department of Physics, University of Florida, Gainesville, Florida 32611, USA
| | - E Fascione
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
- Department of Physics, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - E Figueroa-Feliciano
- Department of Physics & Astronomy, Northwestern University, Evanston, Illinois 60208-3112, USA
| | - C W Fink
- Department of Physics, University of California, Berkeley, California 94720, USA
| | - K Fouts
- SLAC National Accelerator Laboratory/Kavli Institute for Particle Astrophysics and Cosmology, Menlo Park, California 94025, USA
| | - M Fritts
- School of Physics & Astronomy, University of Minnesota, Minneapolis, Minnesota 55455, USA
| | - G Gerbier
- Department of Physics, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - R Germond
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
- Department of Physics, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - M Ghaith
- College of Natural and Health Sciences, Zayed University, Dubai, 19282, United Arab Emirates
| | - S R Golwala
- Division of Physics, Mathematics, & Astronomy, California Institute of Technology, Pasadena, California 91125, USA
| | - J Hall
- SNOLAB, Creighton Mine #9, 1039 Regional Road 24, Sudbury, Ontario P3Y 1N2, Canada
- Laurentian University, Department of Physics, 935 Ramsey Lake Road, Sudbury, Ontario P3E 2C6, Canada
| | - S A S Harms
- Department of Physics, University of Toronto, Toronto, Ontario M5S 1A7, Canada
| | - N Hassan
- Département de Physique, Université de Montréal, Montréal, Québec H3C 3J7, Canada
| | - B A Hines
- Department of Physics, University of Colorado Denver, Denver, Colorado 80217, USA
| | - Z Hong
- Department of Physics, University of Toronto, Toronto, Ontario M5S 1A7, Canada
| | - E W Hoppe
- Pacific Northwest National Laboratory, Richland, Washington 99352, USA
| | - L Hsu
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - M E Huber
- Department of Physics, University of Colorado Denver, Denver, Colorado 80217, USA
- Department of Electrical Engineering, University of Colorado Denver, Denver, Colorado 80217, USA
| | - V Iyer
- Department of Physics, University of Toronto, Toronto, Ontario M5S 1A7, Canada
| | - V K S Kashyap
- School of Physical Sciences, National Institute of Science Education and Research, HBNI, Jatni - 752050, India
| | - M H Kelsey
- Department of Physics and Astronomy, and the Mitchell Institute for Fundamental Physics and Astronomy, Texas A&M University, College Station, Texas 77843, USA
| | - A Kubik
- SNOLAB, Creighton Mine #9, 1039 Regional Road 24, Sudbury, Ontario P3Y 1N2, Canada
| | - N A Kurinsky
- SLAC National Accelerator Laboratory/Kavli Institute for Particle Astrophysics and Cosmology, Menlo Park, California 94025, USA
| | - M Lee
- Department of Physics and Astronomy, and the Mitchell Institute for Fundamental Physics and Astronomy, Texas A&M University, College Station, Texas 77843, USA
| | - M Litke
- Department of Physics, Southern Methodist University, Dallas, Texas 75275, USA
| | - J Liu
- Department of Physics, Southern Methodist University, Dallas, Texas 75275, USA
| | - Y Liu
- Department of Physics & Astronomy, University of British Columbia, Vancouver, British Columbia V6T 1Z1, Canada
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - B Loer
- Pacific Northwest National Laboratory, Richland, Washington 99352, USA
| | - E Lopez Asamar
- Instituto de Física Teórica UAM/CSIC, Universidad Autónoma de Madrid, 28049 Madrid, Spain
- Instituto de Física Teórica UAM-CSIC, Campus de Cantoblanco, 28049 Madrid, Spain
| | - P Lukens
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - D B MacFarlane
- SLAC National Accelerator Laboratory/Kavli Institute for Particle Astrophysics and Cosmology, Menlo Park, California 94025, USA
| | - R Mahapatra
- Department of Physics and Astronomy, and the Mitchell Institute for Fundamental Physics and Astronomy, Texas A&M University, College Station, Texas 77843, USA
| | - N Mast
- School of Physics & Astronomy, University of Minnesota, Minneapolis, Minnesota 55455, USA
| | - A J Mayer
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - H Meyer Zu Theenhausen
- Institute for Astroparticle Physics (IAP), Karlsruhe Institute of Technology (KIT), 76344 Eggenstein-Leopoldshafen, Germany
| | - É Michaud
- Département de Physique, Université de Montréal, Montréal, Québec H3C 3J7, Canada
| | - E Michielin
- Department of Physics & Astronomy, University of British Columbia, Vancouver, British Columbia V6T 1Z1, Canada
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - N Mirabolfathi
- Department of Physics and Astronomy, and the Mitchell Institute for Fundamental Physics and Astronomy, Texas A&M University, College Station, Texas 77843, USA
| | - B Mohanty
- School of Physical Sciences, National Institute of Science Education and Research, HBNI, Jatni - 752050, India
| | - B Nebolsky
- Department of Physics & Astronomy, Northwestern University, Evanston, Illinois 60208-3112, USA
| | - J Nelson
- School of Physics & Astronomy, University of Minnesota, Minneapolis, Minnesota 55455, USA
| | - H Neog
- School of Physics & Astronomy, University of Minnesota, Minneapolis, Minnesota 55455, USA
| | - V Novati
- Department of Physics & Astronomy, Northwestern University, Evanston, Illinois 60208-3112, USA
| | - J L Orrell
- Pacific Northwest National Laboratory, Richland, Washington 99352, USA
| | - M D Osborne
- Department of Physics and Astronomy, and the Mitchell Institute for Fundamental Physics and Astronomy, Texas A&M University, College Station, Texas 77843, USA
| | - S M Oser
- Department of Physics & Astronomy, University of British Columbia, Vancouver, British Columbia V6T 1Z1, Canada
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - W A Page
- Department of Physics, University of California, Berkeley, California 94720, USA
| | - L Pandey
- Department of Physics, University of South Dakota, Vermillion, South Dakota 57069, USA
| | - S Pandey
- School of Physics & Astronomy, University of Minnesota, Minneapolis, Minnesota 55455, USA
| | - R Partridge
- SLAC National Accelerator Laboratory/Kavli Institute for Particle Astrophysics and Cosmology, Menlo Park, California 94025, USA
| | - D S Pedreros
- Département de Physique, Université de Montréal, Montréal, Québec H3C 3J7, Canada
| | - L Perna
- Department of Physics, University of Toronto, Toronto, Ontario M5S 1A7, Canada
| | - R Podviianiuk
- Department of Physics, University of South Dakota, Vermillion, South Dakota 57069, USA
| | - F Ponce
- Pacific Northwest National Laboratory, Richland, Washington 99352, USA
| | - S Poudel
- Department of Physics, University of South Dakota, Vermillion, South Dakota 57069, USA
| | - A Pradeep
- Department of Physics & Astronomy, University of British Columbia, Vancouver, British Columbia V6T 1Z1, Canada
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - M Pyle
- Department of Physics, University of California, Berkeley, California 94720, USA
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - W Rau
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - E Reid
- Department of Physics, Durham University, Durham DH1 3LE, United Kingdom
| | - R Ren
- Department of Physics & Astronomy, Northwestern University, Evanston, Illinois 60208-3112, USA
| | - T Reynolds
- Department of Physics, University of Toronto, Toronto, Ontario M5S 1A7, Canada
| | - E Tanner
- School of Physics & Astronomy, University of Minnesota, Minneapolis, Minnesota 55455, USA
| | - A Roberts
- Department of Physics, University of Colorado Denver, Denver, Colorado 80217, USA
| | - A E Robinson
- Département de Physique, Université de Montréal, Montréal, Québec H3C 3J7, Canada
| | - T Saab
- Department of Physics, University of Florida, Gainesville, Florida 32611, USA
| | - D Sadek
- Department of Physics, University of Florida, Gainesville, Florida 32611, USA
| | - B Sadoulet
- Department of Physics, University of California, Berkeley, California 94720, USA
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - S P Sahoo
- Department of Physics and Astronomy, and the Mitchell Institute for Fundamental Physics and Astronomy, Texas A&M University, College Station, Texas 77843, USA
| | - I Saikia
- Department of Physics, Southern Methodist University, Dallas, Texas 75275, USA
| | - J Sander
- Department of Physics, University of South Dakota, Vermillion, South Dakota 57069, USA
| | - A Sattari
- Department of Physics, University of Toronto, Toronto, Ontario M5S 1A7, Canada
| | - B Schmidt
- Department of Physics & Astronomy, Northwestern University, Evanston, Illinois 60208-3112, USA
| | - R W Schnee
- Department of Physics, South Dakota School of Mines and Technology, Rapid City, South Dakota 57701, USA
| | - S Scorza
- SNOLAB, Creighton Mine #9, 1039 Regional Road 24, Sudbury, Ontario P3Y 1N2, Canada
- Laurentian University, Department of Physics, 935 Ramsey Lake Road, Sudbury, Ontario P3E 2C6, Canada
| | - B Serfass
- Department of Physics, University of California, Berkeley, California 94720, USA
| | - S S Poudel
- Pacific Northwest National Laboratory, Richland, Washington 99352, USA
| | - D J Sincavage
- School of Physics & Astronomy, University of Minnesota, Minneapolis, Minnesota 55455, USA
| | - P Sinervo
- Department of Physics, University of Toronto, Toronto, Ontario M5S 1A7, Canada
| | - Z Speaks
- Department of Physics, University of Florida, Gainesville, Florida 32611, USA
| | - J Street
- Department of Physics, South Dakota School of Mines and Technology, Rapid City, South Dakota 57701, USA
| | - H Sun
- Department of Physics, University of Florida, Gainesville, Florida 32611, USA
| | - G D Terry
- Department of Physics, University of South Dakota, Vermillion, South Dakota 57069, USA
| | - F K Thasrawala
- Institut für Experimentalphysik, Universität Hamburg, 22761 Hamburg, Germany
| | - D Toback
- Department of Physics and Astronomy, and the Mitchell Institute for Fundamental Physics and Astronomy, Texas A&M University, College Station, Texas 77843, USA
| | - R Underwood
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
- Department of Physics, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - S Verma
- Department of Physics and Astronomy, and the Mitchell Institute for Fundamental Physics and Astronomy, Texas A&M University, College Station, Texas 77843, USA
| | - A N Villano
- Department of Physics, University of Colorado Denver, Denver, Colorado 80217, USA
| | - B von Krosigk
- Institute for Astroparticle Physics (IAP), Karlsruhe Institute of Technology (KIT), 76344 Eggenstein-Leopoldshafen, Germany
| | - S L Watkins
- Department of Physics, University of California, Berkeley, California 94720, USA
| | - O Wen
- Division of Physics, Mathematics, & Astronomy, California Institute of Technology, Pasadena, California 91125, USA
| | - Z Williams
- School of Physics & Astronomy, University of Minnesota, Minneapolis, Minnesota 55455, USA
| | - M J Wilson
- Institute for Astroparticle Physics (IAP), Karlsruhe Institute of Technology (KIT), 76344 Eggenstein-Leopoldshafen, Germany
| | - J Winchell
- Department of Physics and Astronomy, and the Mitchell Institute for Fundamental Physics and Astronomy, Texas A&M University, College Station, Texas 77843, USA
| | - K Wykoff
- Department of Physics, South Dakota School of Mines and Technology, Rapid City, South Dakota 57701, USA
| | - S Yellin
- Department of Physics, Stanford University, Stanford, California 94305, USA
| | - B A Young
- Department of Physics, Santa Clara University, Santa Clara, California 95053, USA
| | - T C Yu
- SLAC National Accelerator Laboratory/Kavli Institute for Particle Astrophysics and Cosmology, Menlo Park, California 94025, USA
| | - B Zatschler
- Department of Physics, University of Toronto, Toronto, Ontario M5S 1A7, Canada
| | - S Zatschler
- Department of Physics, University of Toronto, Toronto, Ontario M5S 1A7, Canada
| | - A Zaytsev
- Institute for Astroparticle Physics (IAP), Karlsruhe Institute of Technology (KIT), 76344 Eggenstein-Leopoldshafen, Germany
| | - A Zeolla
- Department of Physics, University of Florida, Gainesville, Florida 32611, USA
| | - E Zhang
- Department of Physics, University of Toronto, Toronto, Ontario M5S 1A7, Canada
| | - L Zheng
- Department of Physics and Astronomy, and the Mitchell Institute for Fundamental Physics and Astronomy, Texas A&M University, College Station, Texas 77843, USA
| | - Y Zheng
- Department of Physics & Astronomy, Northwestern University, Evanston, Illinois 60208-3112, USA
| | - A Zuniga
- Department of Physics, University of Toronto, Toronto, Ontario M5S 1A7, Canada
| | - P An
- Department of Physics, Duke University, Durham, North Carolina 27708, USA
| | - P S Barbeau
- Department of Physics, Duke University, Durham, North Carolina 27708, USA
| | - S C Hedges
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - L Li
- Department of Physics, Duke University, Durham, North Carolina 27708, USA
| | - J Runge
- Department of Physics, Duke University, Durham, North Carolina 27708, USA
| |
Collapse
|
6
|
Costa Silva A, Pina-Vaz T, Manso M, Antunes-Lopes T, Pestana M, Rios M, Martins-Silva C, Morgado A, Silva J. Kidney transplantation from donation after brain death versus donation after circulatory death using abdominal normothermic oxygenated circulation: Is there a difference in surgical complications? Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)00457-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
7
|
Cascais I, Freitas J, Mosca S, Freitas J, Soares T, Morais L, Rios M. Pediatric Polysomnography: Cross-sectional Study. Sleep Med 2022. [DOI: 10.1016/j.sleep.2022.05.545] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
8
|
Jehanno N, Corradini N, Gaspar N, Chevreau C, Gentet JC, Lervat C, Taque S, Entz-Werle N, Mansuy L, Plantaz D, Rios M, Saumet L, Verite C, Castex MP, Thebaud E, Cassou-Mounat T, Mosseri V, Brahmi M, Cordero C, Laurence V. 1506P Role of 18F-FDG PET/CT in the initial staging of very high risk Ewing sarcoma in a prospective multicentric phase II study: Is there still a place for bone marrow sampling? Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1609] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
9
|
Funes SC, Rios M, Fernández-Fierro A, Di Genaro MS, Kalergis AM. Trained Immunity Contribution to Autoimmune and Inflammatory Disorders. Front Immunol 2022; 13:868343. [PMID: 35464438 PMCID: PMC9028757 DOI: 10.3389/fimmu.2022.868343] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2022] [Accepted: 03/16/2022] [Indexed: 12/24/2022] Open
Abstract
A dysregulated immune response toward self-antigens characterizes autoimmune and autoinflammatory (AIF) disorders. Autoantibodies or autoreactive T cells contribute to autoimmune diseases, while autoinflammation results from a hyper-functional innate immune system. Aside from their differences, many studies suggest that monocytes and macrophages (Mo/Ma) significantly contribute to the development of both types of disease. Mo/Ma are innate immune cells that promote an immune-modulatory, pro-inflammatory, or repair response depending on the microenvironment. However, understanding the contribution of these cells to different immune disorders has been difficult due to their high functional and phenotypic plasticity. Several factors can influence the function of Mo/Ma under the landscape of autoimmune/autoinflammatory diseases, such as genetic predisposition, epigenetic changes, or infections. For instance, some vaccines and microorganisms can induce epigenetic changes in Mo/Ma, modifying their functional responses. This phenomenon is known as trained immunity. Trained immunity can be mediated by Mo/Ma and NK cells independently of T and B cell function. It is defined as the altered innate immune response to the same or different microorganisms during a second encounter. The improvement in cell function is related to epigenetic and metabolic changes that modify gene expression. Although the benefits of immune training have been highlighted in a vaccination context, the effects of this type of immune response on autoimmunity and chronic inflammation still remain controversial. Induction of trained immunity reprograms cellular metabolism in hematopoietic stem cells (HSCs), transmitting a memory-like phenotype to the cells. Thus, trained Mo/Ma derived from HSCs typically present a metabolic shift toward glycolysis, which leads to the modification of the chromatin architecture. During trained immunity, the epigenetic changes facilitate the specific gene expression after secondary challenge with other stimuli. Consequently, the enhanced pro-inflammatory response could contribute to developing or maintaining autoimmune/autoinflammatory diseases. However, the prediction of the outcome is not simple, and other studies propose that trained immunity can induce a beneficial response both in AIF and autoimmune conditions by inducing anti-inflammatory responses. This article describes the metabolic and epigenetic mechanisms involved in trained immunity that affect Mo/Ma, contraposing the controversial evidence on how it may impact autoimmune/autoinflammation conditions.
Collapse
Affiliation(s)
- Samanta C. Funes
- Instituto Multidisciplinario de Investigaciones Biológicas-San Luis (IMIBIO-SL), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Universidad Nacional de San Luis (UNSL), San Luis, Argentina
| | - Mariana Rios
- Millennium Institute on Immunology and Immunotherapy, Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - Ayleen Fernández-Fierro
- Millennium Institute on Immunology and Immunotherapy, Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - María S. Di Genaro
- Instituto Multidisciplinario de Investigaciones Biológicas-San Luis (IMIBIO-SL), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Universidad Nacional de San Luis (UNSL), San Luis, Argentina
| | - Alexis M. Kalergis
- Millennium Institute on Immunology and Immunotherapy, Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile
- Departamento de Endocrinología, Escuela de Medicina, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile
- *Correspondence: Alexis M. Kalergis,
| |
Collapse
|
10
|
Le Cesne A, Blay JY, Cupissol D, Italiano A, Delcambre C, Penel N, Isambert N, Chevreau C, Bompas E, Bertucci F, Chaigneau L, Piperno-Neumann S, Salas S, Rios M, Guillemet C, Bay JO, Ray-Coquard I, Haddag L, Bonastre J, Kapso R, Fraslin A, Bouvet N, Mir O, Foulon S. A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial. Ann Oncol 2021; 32:1034-1044. [PMID: 33932507 DOI: 10.1016/j.annonc.2021.04.014] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2021] [Revised: 04/20/2021] [Accepted: 04/22/2021] [Indexed: 01/18/2023] Open
Abstract
BACKGROUND The French Sarcoma Group assessed the efficacy, safety, and quality of life (QoL) of trabectedin versus best supportive care (BSC) in patients with advanced soft tissue sarcoma (STS). PATIENTS AND METHODS This randomized, multicenter, open-label, phase III study included adults with STS who progressed after 1-3 prior treatment lines. Patients were randomized (1 : 1) to receive trabectedin 1.5 mg/m2 every 3 weeks or BSC, stratified into L-STS (liposarcoma/leiomyosarcoma) and non-L-STS groups (other histotypes). Patients from the BSC arm were allowed to cross over to trabectedin at progression. The primary efficacy endpoint was progression-free survival (PFS) confirmed by blinded central review and analyzed in the intention-to-treat population. RESULTS Between 26 January 2015 and 5 November 2015, 103 heavily pre-treated patients (60.2% with L-STS) from 16 French centers were allocated to receive trabectedin (n = 52) or BSC (n = 51). Median PFS was 3.1 months [95% confidence interval (CI) 1.8-5.9 months] in the trabectedin arm versus 1.5 months (0.9-2.6 months) in the BSC arm (hazard ratio = 0.39, 95% CI 0.24-0.64, P < 0.001) with benefits observed across almost all analyzed subgroups, but particularly in patients with L-STS (5.1 versus 1.4 months, P = 0.0001). Seven patients (13.7%) in the trabectedin arm (all with L-STS) achieved a partial response, while no objective responses were observed in the BSC arm (P = 0.004). The most common grade 3/4 adverse events were neutropenia (44.2% of patients), leukopenia (34.6%), and transaminase increase (32.7%). Health-related 30-item core European Organization for the Research and Treatment of Cancer Quality-of-Life Questionnaire evidenced no statistical differences between the arms for any domain and at any time point. After progression, 91.8% of patients crossed over from BSC to trabectedin. CONCLUSION Trabectedin demonstrates superior disease control to BSC without impairing QoL in patients with recurrent STS of multiple histologies, with greater impact in patients with L-STS.
Collapse
Affiliation(s)
- A Le Cesne
- Medical Oncology Department, Gustave Roussy, Villejuif, France.
| | - J-Y Blay
- Medical Oncology Department, Centre Léon Bérard and Claude Bernard University, Lyon, France
| | - D Cupissol
- Medical Oncology Department, Centre Val d'Aurelle, Montpellier, France
| | - A Italiano
- Medical Oncology Department, Institut Bergonié, Bordeaux, France
| | - C Delcambre
- Medical Oncology Department, Centre François Baclesse, Caen, France
| | - N Penel
- Medical Oncology Department, Centre Oscar Lambret and Lille University, Lille, France
| | - N Isambert
- Medical Oncology Department, Centre Georges-François Leclerc, Dijon, France
| | - C Chevreau
- Medical Oncology Department, Institut Claudius Regaud, Toulouse, France
| | - E Bompas
- Medical Oncology Department, Centre René Gauduchau, Nantes, France
| | - F Bertucci
- Medical Oncology Department, Institut Paoli-Calmettes, Marseille, France
| | - L Chaigneau
- Medical Oncology Department, Hôpital Jean Minjoz, Besancon, France
| | | | - S Salas
- Medical Oncology Department, Hôpital La Timone, Marseille, France
| | - M Rios
- Medical Oncology Department, Institut de Cancerologie de Lorraine, Nancy, France
| | - C Guillemet
- Medical Oncology Department, Centre Henri Becquerel, Rouen, France
| | - J-O Bay
- Medical Oncology Department, Centre Jean Perrin, Clermont Ferrand, France
| | - I Ray-Coquard
- Medical Oncology Department, Centre Léon Bérard and Claude Bernard University, Lyon, France
| | - L Haddag
- Department of Radiology, Gustave Roussy, Villejuif, France
| | - J Bonastre
- Department of Biostatistics and Epidemiology, Gustave Roussy, Villejuif, France; Oncostat U1018, Inserm, University Paris-Saclay, Labeled Ligue Contre le Cancer, Villejuif, France
| | - R Kapso
- Department of Biostatistics and Epidemiology, Gustave Roussy, Villejuif, France; Oncostat U1018, Inserm, University Paris-Saclay, Labeled Ligue Contre le Cancer, Villejuif, France
| | - A Fraslin
- Department of Biostatistics and Epidemiology, Gustave Roussy, Villejuif, France; Oncostat U1018, Inserm, University Paris-Saclay, Labeled Ligue Contre le Cancer, Villejuif, France
| | - N Bouvet
- Department of Biostatistics and Epidemiology, Gustave Roussy, Villejuif, France
| | - O Mir
- Medical Oncology Department, Gustave Roussy, Villejuif, France
| | - S Foulon
- Department of Biostatistics and Epidemiology, Gustave Roussy, Villejuif, France; Oncostat U1018, Inserm, University Paris-Saclay, Labeled Ligue Contre le Cancer, Villejuif, France
| |
Collapse
|
11
|
Aitken ML, Somayaji R, Hinds TR, Pier M, Droguett K, Rios M, Skerrett SJ, Villalon M. Glycated Albumin Triggers an Inflammatory Response in the Human Airway Epithelium and Causes an Increase in Ciliary Beat Frequency. Front Physiol 2021; 12:653177. [PMID: 33967824 PMCID: PMC8102681 DOI: 10.3389/fphys.2021.653177] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2021] [Accepted: 03/17/2021] [Indexed: 01/30/2023] Open
Abstract
The role of inflammation in airway epithelial cells and its regulation are important in several respiratory diseases. When disease is present, the barrier between the pulmonary circulation and the airway epithelium is damaged, allowing serum proteins to enter the airways. We identified that human glycated albumin (GA) is a molecule in human serum that triggers an inflammatory response in human airway epithelial cultures. We observed that single-donor human serum induced IL-8 secretion from primary human airway epithelial cells and from a cystic fibrosis airway cell line (CF1-16) in a dose-dependent manner. IL-8 secretion from airway epithelial cells was time dependent and rapidly increased in the first 4 h of incubation. Stimulation with GA promoted epithelial cells to secrete IL-8, and this increase was blocked by the anti-GA antibody. The IL-8 secretion induced by serum GA was 10–50-fold more potent than TNFα or LPS stimulation. GA also has a functional effect on airway epithelial cells in vitro, increasing ciliary beat frequency. Our results demonstrate that the serum molecule GA is pro-inflammatory and triggers host defense responses including increases in IL-8 secretion and ciliary beat frequency in the human airway epithelium. Although the binding site of GA has not yet been described, it is possible that GA could bind to the receptor for advanced glycated end products (RAGE), known to be expressed in the airway epithelium; however, further experiments are needed to identify the mechanism involved. We highlight a possible role for GA in airway inflammation.
Collapse
Affiliation(s)
- Moira L Aitken
- Department of Medicine, School of Medicine, University of Washington, Seattle, WA, United States
| | - Ranjani Somayaji
- Department of Medicine, School of Medicine, University of Washington, Seattle, WA, United States
| | - Thomas R Hinds
- Department of Pharmacy, School of Medicine, University of Washington, Seattle, WA, United States
| | - Maricela Pier
- Department of Medicine, School of Medicine, University of Washington, Seattle, WA, United States
| | - Karla Droguett
- Department of Physiology, Faculty of Biological Sciences, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - Mariana Rios
- Department of Physiology, Faculty of Biological Sciences, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - Shawn J Skerrett
- Department of Medicine, School of Medicine, University of Washington, Seattle, WA, United States.,Department of Physiology, Faculty of Biological Sciences, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - Manuel Villalon
- Department of Physiology, Faculty of Biological Sciences, Pontificia Universidad Católica de Chile, Santiago, Chile
| |
Collapse
|
12
|
Fernández-Fierro A, Funes SC, Rios M, Covián C, González J, Kalergis AM. Immune Modulation by Inhibitors of the HO System. Int J Mol Sci 2020; 22:ijms22010294. [PMID: 33396647 PMCID: PMC7794909 DOI: 10.3390/ijms22010294] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2020] [Revised: 12/16/2020] [Accepted: 12/18/2020] [Indexed: 12/23/2022] Open
Abstract
The heme oxygenase (HO) system involves three isoforms of this enzyme, HO-1, HO-2, and HO-3. The three of them display the same catalytic activity, oxidating the heme group to produce biliverdin, ferrous iron, and carbon monoxide (CO). HO-1 is the isoform most widely studied in proinflammatory diseases because treatments that overexpress this enzyme promote the generation of anti-inflammatory products. However, neonatal jaundice (hyperbilirubinemia) derived from HO overexpression led to the development of inhibitors, such as those based on metaloproto- and meso-porphyrins inhibitors with competitive activity. Further, non-competitive inhibitors have also been identified, such as synthetic and natural imidazole-dioxolane-based, small synthetic molecules, inhibitors of the enzyme regulation pathway, and genetic engineering using iRNA or CRISPR cas9. Despite most of the applications of the HO inhibitors being related to metabolic diseases, the beneficial effects of these molecules in immune-mediated diseases have also emerged. Different medical implications, including cancer, Alzheimer´s disease, and infections, are discussed in this article and as to how the selective inhibition of HO isoforms may contribute to the treatment of these ailments.
Collapse
Affiliation(s)
- Ayleen Fernández-Fierro
- Millenium Institute on Immunology and Immunotherapy, Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, 8331150 Santiago, Chile; (A.F.-F.); (M.R.); (C.C.); (J.G.)
| | - Samanta C. Funes
- Instituto Multidisciplinario de Investigaciones Biológicas-San Luis, Consejo Nacional de Investigaciones Científicas y Técnicas—Universidad Nacional de San Luis, 5700 San Luis, Argentina;
| | - Mariana Rios
- Millenium Institute on Immunology and Immunotherapy, Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, 8331150 Santiago, Chile; (A.F.-F.); (M.R.); (C.C.); (J.G.)
| | - Camila Covián
- Millenium Institute on Immunology and Immunotherapy, Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, 8331150 Santiago, Chile; (A.F.-F.); (M.R.); (C.C.); (J.G.)
| | - Jorge González
- Millenium Institute on Immunology and Immunotherapy, Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, 8331150 Santiago, Chile; (A.F.-F.); (M.R.); (C.C.); (J.G.)
| | - Alexis M. Kalergis
- Millenium Institute on Immunology and Immunotherapy, Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, 8331150 Santiago, Chile; (A.F.-F.); (M.R.); (C.C.); (J.G.)
- Departamento de Endocrinología, Facultad de Medicina, Pontificia Universidad Católica de Chile, 8331150 Santiago, Chile
- Correspondence: ; Tel.: +56-22-686-2842
| |
Collapse
|
13
|
Funes SC, Rios M, Fernández-Fierro A, Covián C, Bueno SM, Riedel CA, Mackern-Oberti JP, Kalergis AM. Naturally Derived Heme-Oxygenase 1 Inducers and Their Therapeutic Application to Immune-Mediated Diseases. Front Immunol 2020; 11:1467. [PMID: 32849503 PMCID: PMC7396584 DOI: 10.3389/fimmu.2020.01467] [Citation(s) in RCA: 82] [Impact Index Per Article: 20.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2020] [Accepted: 06/05/2020] [Indexed: 02/06/2023] Open
Abstract
Heme oxygenase (HO) is the primary antioxidant enzyme involved in heme group degradation. A variety of stimuli triggers the expression of the inducible HO-1 isoform, which is modulated by its substrate and cellular stressors. A major anti-inflammatory role has been assigned to the HO-1 activity. Therefore, in recent years HO-1 induction has been employed as an approach to treating several disorders displaying some immune alterations components, such as exacerbated inflammation or self-reactivity. Many natural compounds have shown to be effective inductors of HO-1 without cytotoxic effects; among them, most are chemicals present in plants used as food, flavoring, and medicine. Here we discuss some naturally derived compounds involved in HO-1 induction, their impact in the immune response modulation, and the beneficial effect in diverse autoimmune disorders. We conclude that the use of some compounds from natural sources able to induce HO-1 is an attractive lifestyle toward promoting human health. This review opens a new outlook on the investigation of naturally derived HO-1 inducers, mainly concerning autoimmunity.
Collapse
Affiliation(s)
- Samanta C Funes
- Departamento de Genética Molecular y Microbiología, Millenium Institute on Immunology and Immunotherapy, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - Mariana Rios
- Departamento de Genética Molecular y Microbiología, Millenium Institute on Immunology and Immunotherapy, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - Ayleen Fernández-Fierro
- Departamento de Genética Molecular y Microbiología, Millenium Institute on Immunology and Immunotherapy, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - Camila Covián
- Departamento de Genética Molecular y Microbiología, Millenium Institute on Immunology and Immunotherapy, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - Susan M Bueno
- Departamento de Genética Molecular y Microbiología, Millenium Institute on Immunology and Immunotherapy, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - Claudia A Riedel
- Departamento de Ciencias Biológicas, Millenium Institute on Immunolgy and Immunotherapy, Facultad Ciencias de la Vida, Universidad Andrés Bello, Santiago, Chile
| | - Juan Pablo Mackern-Oberti
- Instituto de Medicina y Biología Experimental de Cuyo, IMBECU CCT Mendoza- CONICET, Mendoza, Argentina.,Facultad de Ciencias Médicas, Instituto de Fisiología, Universidad Nacional de Cuyo, Mendoza, Argentina
| | - Alexis M Kalergis
- Departamento de Genética Molecular y Microbiología, Millenium Institute on Immunology and Immunotherapy, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile.,Departamento de Endocrinología, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile
| |
Collapse
|
14
|
Pautier P, Penel N, Ray-Coquard I, Italiano A, Bompas E, Delcambre C, Bay JO, Bertucci F, Delaye J, Chevreau C, Cupissol D, Bozec L, Eymard JC, Saada E, Isambert N, Guillemet C, Rios M, Piperno-Neumann S, Chenuc G, Duffaud F. A phase II of gemcitabine combined with pazopanib followed by pazopanib maintenance, as second-line treatment in patients with advanced leiomyosarcomas: A unicancer French Sarcoma Group study (LMS03 study). Eur J Cancer 2019; 125:31-37. [PMID: 31835236 DOI: 10.1016/j.ejca.2019.10.028] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2019] [Revised: 10/08/2019] [Accepted: 10/12/2019] [Indexed: 10/25/2022]
Abstract
BACKGROUND Options in second-line therapy after doxorubicin-based chemotherapy for metastatic/advanced leiomyosarcoma include gemcitabine (G), trabectedin and pazopanib (P) monotherapy. Currently, no combination therapy is better than monotherapy. LMS03 is an open-label multicentre single-group phase II study designed to assess the efficacy and tolerance of G + P in the second-line setting. PATIENTS AND METHODS Patients (pts), ECOG ≤2, with metastatic leiomyosarcomas (LMS) after first-line doxorubicin chemotherapy failure were eligible. Pts were treated with G 1000 mg/m2 on days 1 and 8 of each 21 days (maximum eight cycles), in combination with oral daily P (800 mg), until disease progression/toxicity. 9-month progression-free survival (PFS) rate was the primary endpoint. Inacceptable and promising 9-month PFS rates were defined, in the intent-to-treat population, as 32% and 44%. RESULTS 106 pts were included with a mean age of 59.8 years and an ECOG 0 in 63.5%; the primary tumour site was uterus in 61%. Pts were treated with P + G for a median of 3.8 mo, and P for a median of 4.2 mo. The 9-month PFS rate was 32.1% (95% CI 23.1-41.1). After a median follow-up of 14.2 months, the PFS was 6.5 months (95% CI 5.6-8.2), and the overall survival was 22.4 months (95% CI 16.9-26.5). The best response was 23.8%. The most frequent reported grade 3-4 adverse events were haematological. CONCLUSIONS LMS03 failed to show that second-line therapy, with gemcitabine combined with pazopanib, followed by pazopanib alone, was beneficial for advanced LMS patients. Eudract N°2011-001308-36 and NCT01442662.
Collapse
Affiliation(s)
| | - N Penel
- Centre Oscar-Lambret & Lille University, Lille, France
| | - I Ray-Coquard
- Centre Léon-Bérard & University Claude Bernard Lyon Est, Lyon, France
| | | | - E Bompas
- Institut de Cancérologie de L'Ouest, Angers-Nantes, France
| | | | - J-O Bay
- Centre Jean-Perrin, Clermont-Ferrand, France
| | - F Bertucci
- Institut Paoli-Calmettes, Marseille, France
| | | | - C Chevreau
- Institut Claudius-Regaud, Toulouse, France
| | | | - L Bozec
- Institut Curie, Hôpital René-Huguenin, Saint-Cloud, France
| | | | - E Saada
- Centre Antoine-Lacassagne, Nice, France
| | - N Isambert
- Centre Georges-François-Leclerc, Dijon, France
| | | | - M Rios
- Centre Alexis-Vautrin, Vandoeuvre-les-Nancy, France
| | | | | | | |
Collapse
|
15
|
Takacs J, Ciotti M, Tsolova S, Wiltshire E, Baka A, Kinsman J, de Vries D, Cremers L, Rios M, Angrén J. Community engagement in public health emergency preparedness. Eur J Public Health 2019. [DOI: 10.1093/eurpub/ckz186.514] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Communities that could be affected by infectious disease outbreaks are increasingly recognised as resources that may be effectively utilized by the authorities during public health emergencies.
Methods
This case study project, aiming to identify synergies between communities and authorities, was based on qualitative sources of evidence, including document and media review, stakeholder mapping, interviews and FGDs (N = 137). Four countries were selected for inclusion: Spain and the Netherlands on the basis of emerging tick-born disease incidents; Iceland and Ireland on the basis of acute gastroenteritis outbreaks.
Results
In the Netherlands and Spain strong synergies were identified in tick surveillance activities, and the value of pre-existing networks of interest groups for preparedness and response activities was recognised. The Icelandic norovirus event was unexpected and fast-moving, while VTEC in Ireland is a familiar and slower-burning challenge. As a relatively common disease in Ireland, VTEC-protocols are closely followed, while a generic all-hazards approach was taken in Iceland. There was considerable community support in the responses in both countries., and in Iceland community representatives also actively participated in producing institutional post-event evaluations.
Conclusions
An over-riding principle emerging from this study is that an informed, at-risk community understands the challenges to adopting effective preventive practices for themselves better than anyone. Additional good practices included the utilisation of pre-existing stakeholder networks for information dissemination; and of monitoring community perceptions of any public health incident, including through social media, in order to identify and manage misperceptions. Efforts to build on the community engagement activities that are already in place in the four countries could contribute to better preparedness planning and more efficient and timely responses in future outbreaks.
Key messages
Recognise the community as a real partner in outbreak preparedness, response, and recovery. Optimise communications with communities who may be affected by outbreaks.
Collapse
Affiliation(s)
| | | | | | | | | | - J Kinsman
- ECDC, Solna, Sweden
- Epidemiology and Global Health Unit, Umeå University, Umeå, Sweden
- Karolinska Institutet, Solna, Sweden
| | - D de Vries
- University of Amsterdam, Amsterdam, Netherlands
| | - L Cremers
- University of Amsterdam, Amsterdam, Netherlands
| | - M Rios
- University of Amsterdam, Amsterdam, Netherlands
| | - J Angrén
- Public Health Institute, Solna, Sweden
| |
Collapse
|
16
|
Duffaud F, Blay JY, Italiano A, Bompas E, Rios M, Penel N, Mir O, Piperno-Neumann S, Chevreau C, Delcambre C, Bertucci F, Boudou Rouquette P, Vegas H, Perrin C, Thyss A, Schiffler C, Monard L, Bouvier C, Vidal V, Chabaud S. Results of the randomized, placebo (PL)-controlled phase II study evaluating the efficacy and safety of regorafenib (REG) in patients (pts) with locally advanced (LA) or metastatic relapsed chondrosarcoma (CS), on behalf of the French Sarcoma Group (FSG) and UNICANCER. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz394.088] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
17
|
Gondim Teixeira PA, Biouichi H, Abou Arab W, Rios M, Sirveaux F, Hossu G, Blum A. Evidence-based MR imaging follow-up strategy for desmoid-type fibromatosis. Eur Radiol 2019; 30:895-902. [PMID: 31468156 DOI: 10.1007/s00330-019-06404-4] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2019] [Revised: 07/04/2019] [Accepted: 07/29/2019] [Indexed: 10/26/2022]
Abstract
OBJECTIVES To propose a follow-up strategy for desmoid-type fibromatosis (DF) based on tumor growth behavior and the signal on T2-weighted MRI. METHODS We retrospectively reviewed 296 MRI studies of 34 patients with histologically proven DF. In each study, tumor volume and T2 signal relatively normal striated muscle were assessed. Volume variation and monthly growth rates were analyzed to determine lesion growth behavior (progressing versus stable/regressing lesions). Growth behavior was correlated with T2 signal, tumor location, β-catenin status, treatment strategy, and follow-up duration. Interobserver variability of volume measurements and interobserver measurement variation ratio were assessed. RESULTS There were 25 women and 9 men with a mean age of 39.9 ± 19 (4-73) years. Mean follow-up time in the patients included was 55 ± 41 (12-148) months. In progressing lesions, the mean average monthly growth ratio was 10.9 ± 9.2 (1.1-42.5) %. Interobserver variability of volume measurements was excellent (ICC = 0.96). Mean interobserver measurement variation ratio was 20.4 ± 23.6%. The only factor correlated with tumor growth behavior was T2 signal ratio (p < 0.0001). Seventeen out of 34 (50%) patients presented a signal change over the threshold of 1 during follow-up. There were five occurrences of secondary growth after a period of stability with a mean delay until growth of 38.2 ± 44.2 (17-116) months. CONCLUSION DF growth rate was quantitatively assessed. A threshold for volume variation detection was established. DF growth behavior was significantly related to T2 signal. An evidence-based follow-up strategy is proposed. KEY POINTS • In progressing desmoid fibromatosis, the mean average monthly growth ratio was 10.9 ± 9.2%. • Lesions with muscle/tumor T2 signal ratios lower than 1 tended to be stable or regress over time. • Given the interobserver measurement variability and MRI in-plane spatial resolution, a variation higher than 42.6% in tumor volume is required to confirm punctual progression.
Collapse
Affiliation(s)
- P A Gondim Teixeira
- Guilloz Imaging Department, Central Hospital, Regional University Hospital Center of Nancy (CHRU-Nancy), 29 avenue du Maréchal de Lattre de Tassigny, 54035, Nancy, France.
| | - H Biouichi
- Guilloz Imaging Department, Central Hospital, Regional University Hospital Center of Nancy (CHRU-Nancy), 29 avenue du Maréchal de Lattre de Tassigny, 54035, Nancy, France
| | - W Abou Arab
- Guilloz Imaging Department, Central Hospital, Regional University Hospital Center of Nancy (CHRU-Nancy), 29 avenue du Maréchal de Lattre de Tassigny, 54035, Nancy, France
| | - M Rios
- Lorraine Cancer Institute, Vandoeuvre-lès-Nancy, France
| | - F Sirveaux
- Emile Gallé Surgical Center, Regional University Hospital Center of Nancy, Nancy, France
| | - G Hossu
- Inserm, IADI, Université de Lorraine, Nancy, France
| | - A Blum
- Guilloz Imaging Department, Central Hospital, Regional University Hospital Center of Nancy (CHRU-Nancy), 29 avenue du Maréchal de Lattre de Tassigny, 54035, Nancy, France
| |
Collapse
|
18
|
Blay JY, Honoré C, Stoeckle E, Meeus P, Jafari M, Gouin F, Anract P, Ferron G, Rochwerger A, Ropars M, Carrere S, Marchal F, Sirveaux F, Di Marco A, Le Nail LR, Guiramand J, Vaz G, Machiavello JC, Marco O, Causeret S, Gimbergues P, Fiorenza F, Chaigneau L, Guillemin F, Guilloit JM, Dujardin F, Spano JP, Ruzic JC, Michot A, Soibinet P, Bompas E, Chevreau C, Duffaud F, Rios M, Perrin C, Firmin N, Bertucci F, Le Pechoux C, Le Loarer F, Collard O, Karanian-Philippe M, Brahmi M, Dufresne A, Dupré A, Ducimetière F, Giraud A, Pérol D, Toulmonde M, Ray-Coquard I, Italiano A, Le Cesne A, Penel N, Bonvalot S. Surgery in reference centers improves survival of sarcoma patients: a nationwide study. Ann Oncol 2019; 30:1407. [PMID: 31168580 PMCID: PMC6683855 DOI: 10.1093/annonc/mdz170] [Citation(s) in RCA: 28] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
|
19
|
Blay JY, Honoré C, Stoeckle E, Meeus P, Jafari M, Gouin F, Anract P, Ferron G, Rochwerger A, Ropars M, Carrere S, Marchal F, Sirveaux F, Di Marco A, Le Nail LR, Guiramand J, Vaz G, Machiavello JC, Marco O, Causeret S, Gimbergues P, Fiorenza F, Chaigneau L, Guillemin F, Guilloit JM, Dujardin F, Spano JP, Ruzic JC, Michot A, Soibinet P, Bompas E, Chevreau C, Duffaud F, Rios M, Perrin C, Firmin N, Bertucci F, Le Pechoux C, Le Loarer F, Collard O, Karanian-Philippe M, Brahmi M, Dufresne A, Dupré A, Ducimetière F, Giraud A, Pérol D, Toulmonde M, Ray-Coquard I, Italiano A, Le Cesne A, Penel N, Bonvalot S. Surgery in reference centers improves survival of sarcoma patients: a nationwide study. Ann Oncol 2019; 30:1143-1153. [PMID: 31081028 PMCID: PMC6637376 DOI: 10.1093/annonc/mdz124] [Citation(s) in RCA: 158] [Impact Index Per Article: 31.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023] Open
Abstract
BACKGROUND NETSARC (netsarc.org) is a network of 26 sarcoma reference centers with specialized multidisciplinary tumor boards (MDTB) aiming to improve the outcome of sarcoma patients. Since 2010, presentation to an MDTB and expert pathological review are mandatory for sarcoma patients nationwide. In the present work, the impact of surgery in a reference center on the survival of sarcoma patients investigated using this national NETSARC registry. PATIENTS AND METHODS Patients' characteristics and follow-up are prospectively collected and data monitored. Descriptive, uni- and multivariate analysis of prognostic factors were conducted in the entire series (N = 35 784) and in the subgroup of incident patient population (N = 29 497). RESULTS Among the 35 784 patients, 155 different histological subtypes were reported. 4310 (11.6%) patients were metastatic at diagnosis. Previous cancer, previous radiotherapy, neurofibromatosis type 1 (NF1), and Li-Fraumeni syndrome were reported in 12.5%, 3.6%, 0.7%, and 0.1% of patients respectively. Among the 29 497 incident patients, 25 851 (87.6%) patients had surgical removal of the sarcoma, including 9949 (33.7%) operated in a NETSARC center. Location, grade, age, size, depth, histotypes, gender, NF1, and surgery outside a NETSARC center all correlated to overall survival (OS), local relapse free survival (LRFS), and event-free survival (EFS) in the incident patient population. NF1 history was one of the strongest adverse prognostic factors for LRFS, EFS, and OS. Presentation to an MDTB was associated with an improved LRFS and EFS, but was an adverse prognostic factor for OS if surgery was not carried out in a reference center. In multivariate analysis, surgery in a NETSARC center was positively correlated with LRFS, EFS, and OS [P < 0.001 for all, with a hazard ratio of 0.681 (95% CI 0.618-0.749) for OS]. CONCLUSION This nationwide registry of sarcoma patients shows that surgical treatment in a reference center reduces the risk of relapse and death.
Collapse
Affiliation(s)
- J-Y Blay
- Department of Medical Oncology and Department of Surgical Oncology, Centre Léon Bérard, Lyon; Université Claude Bernard, Lyon; Institut de Cancerologie L. Neuwirth.
| | - C Honoré
- Department of Medical Oncology and Department of Surgical Oncology, Gustave Roussy Cancer Campus-Surgery, Villejuif
| | - E Stoeckle
- Department of Medical Oncology and Department of Surgical Oncology, Institut Bergonié, Bordeaux
| | - P Meeus
- Department of Medical Oncology and Department of Surgical Oncology, Centre Léon Bérard, Lyon; Université Claude Bernard, Lyon; Institut de Cancerologie L. Neuwirth
| | - M Jafari
- Department of Medical Oncology and Department of Surgical Oncology, Centre Oscar Lambret, Lille; Department of Surgical Oncology, CHU, Lille
| | - F Gouin
- Department of Medical Oncology and Department of Surgical Oncology, Centre Léon Bérard, Lyon; Université Claude Bernard, Lyon; Institut de Cancerologie L. Neuwirth; Department of Medical Oncology and Department of Surgical Oncology, Institut de Cancerologie Nantes, Nantes; Department of Orthopedics, CHU Nantes, Nantes
| | - P Anract
- Department of Orthopedics, Hôpital Cochin-Saint-Vincent de Paul, Paris
| | - G Ferron
- Department of Medical Oncology and Department of Surgical Oncology, Institut Universitaire de Cancerologie de Toulouse, Claudius Regaud, Toulouse
| | - A Rochwerger
- Department of Medical Oncology and Department of Orthopedics, La Timone University Hospital, Marseille
| | - M Ropars
- Medical Oncology Department, Eugene Marquis Comprehensive Cancer Center, Rennes; Department of Orthopedics, CHU, Rennes
| | - S Carrere
- Medical Oncology Department, Institut de Cancérologie de Montpellier, Montpellier
| | - F Marchal
- Department of Medical Oncology and Department of Surgical Oncology, Centre Alexis Vautrin, Vandoeuvre-lès-Nancy
| | - F Sirveaux
- Department of Medical Oncology and Department of Surgical Oncology, Centre Alexis Vautrin, Vandoeuvre-lès-Nancy
| | - A Di Marco
- Department of Surgical Oncology and Department of Medical Oncology, Centre Paul Strauss & CHU Strasbourg, Hôpitaux Universitaires de Strasbourg, Strasbourg
| | - L R Le Nail
- Department of Orthopedics, CHU de Tours, Tours
| | - J Guiramand
- Department of Medical Oncology and Department of Surgical Oncology, Institut Paoli Calmettes, Marseille
| | - G Vaz
- Department of Medical Oncology and Department of Surgical Oncology, Centre Léon Bérard, Lyon; Université Claude Bernard, Lyon; Institut de Cancerologie L. Neuwirth
| | - J-C Machiavello
- Department of Medical Oncology and Department of Surgical Oncology, Centre Antoine-Lacassagne, Nice
| | - O Marco
- Oncology Unit, Saint Louis Hospital, Paris
| | - S Causeret
- Department of Surgery, Centre Georges François Leclerc, Dijon
| | - P Gimbergues
- Department of Surgery, Centre Jean Perrin/ERTICa EA, Clermont-Ferrand
| | - F Fiorenza
- Department of Medical Oncology and Department of Surgical Oncology, CHU Limoges, Limoges
| | - L Chaigneau
- Medical Oncology Department, CHU Besancon, Besançon
| | - F Guillemin
- Department of Medical Oncology and Department of Surgical Oncology, Institut J Godinot Reims
| | - J-M Guilloit
- Department of Surgical Oncology, Centre Francois Baclesse, Caen
| | - F Dujardin
- Department of Surgery, Centre Henri Becquerel, Rouen
| | - J-P Spano
- Medical Oncology Department, APHP La Pitié Salpetriere/Tenon/Bicetre, Paris
| | - J-C Ruzic
- Medical Oncology Department, CHU La Réunion, Saint-Pierre, La Réunion
| | - A Michot
- Department of Medical Oncology and Department of Surgical Oncology, Gustave Roussy Cancer Campus-Surgery, Villejuif
| | - P Soibinet
- Department of Medical Oncology and Department of Surgical Oncology, Institut J Godinot Reims
| | - E Bompas
- Department of Medical Oncology and Department of Surgical Oncology, Institut de Cancerologie Nantes, Nantes; Department of Orthopedics, CHU Nantes, Nantes
| | - C Chevreau
- Department of Medical Oncology and Department of Surgical Oncology, Institut Universitaire de Cancerologie de Toulouse, Claudius Regaud, Toulouse
| | - F Duffaud
- Department of Medical Oncology and Department of Orthopedics, La Timone University Hospital, Marseille
| | - M Rios
- Medical Oncology Department, Eugene Marquis Comprehensive Cancer Center, Rennes; Department of Orthopedics, CHU, Rennes
| | - C Perrin
- Medical Oncology Department, Eugene Marquis Comprehensive Cancer Center, Rennes; Department of Orthopedics, CHU, Rennes
| | - N Firmin
- Medical Oncology Department, Institut de Cancérologie de Montpellier, Montpellier
| | - F Bertucci
- Department of Medical Oncology and Department of Surgical Oncology, Institut Paoli Calmettes, Marseille
| | - C Le Pechoux
- Department of Medical Oncology and Department of Surgical Oncology, Gustave Roussy Cancer Campus-Surgery, Villejuif
| | - F Le Loarer
- Department of Medical Oncology and Department of Surgical Oncology, Gustave Roussy Cancer Campus-Surgery, Villejuif
| | - O Collard
- Department of Medical Oncology and Department of Surgical Oncology, Centre Léon Bérard, Lyon; Université Claude Bernard, Lyon; Institut de Cancerologie L. Neuwirth
| | - M Karanian-Philippe
- Department of Medical Oncology and Department of Surgical Oncology, Centre Léon Bérard, Lyon; Université Claude Bernard, Lyon; Institut de Cancerologie L. Neuwirth
| | - M Brahmi
- Department of Medical Oncology and Department of Surgical Oncology, Centre Léon Bérard, Lyon; Université Claude Bernard, Lyon; Institut de Cancerologie L. Neuwirth
| | - A Dufresne
- Department of Medical Oncology and Department of Surgical Oncology, Centre Léon Bérard, Lyon; Université Claude Bernard, Lyon; Institut de Cancerologie L. Neuwirth
| | - A Dupré
- Department of Medical Oncology and Department of Surgical Oncology, Centre Léon Bérard, Lyon; Université Claude Bernard, Lyon; Institut de Cancerologie L. Neuwirth
| | - F Ducimetière
- Department of Medical Oncology and Department of Surgical Oncology, Centre Léon Bérard, Lyon; Université Claude Bernard, Lyon; Institut de Cancerologie L. Neuwirth
| | - A Giraud
- Department of Orthopedics, Hôpital Cochin-Saint-Vincent de Paul, Paris
| | - D Pérol
- Department of Medical Oncology and Department of Surgical Oncology, Centre Léon Bérard, Lyon; Université Claude Bernard, Lyon; Institut de Cancerologie L. Neuwirth
| | - M Toulmonde
- Department of Medical Oncology and Department of Surgical Oncology, Institut Bergonié, Bordeaux
| | - I Ray-Coquard
- Department of Medical Oncology and Department of Surgical Oncology, Centre Léon Bérard, Lyon; Université Claude Bernard, Lyon; Institut de Cancerologie L. Neuwirth
| | - A Italiano
- Department of Medical Oncology and Department of Surgical Oncology, Institut Bergonié, Bordeaux
| | - A Le Cesne
- Department of Medical Oncology and Department of Surgical Oncology, Gustave Roussy Cancer Campus-Surgery, Villejuif
| | - N Penel
- Department of Medical Oncology and Department of Surgical Oncology, Centre Oscar Lambret, Lille; Department of Surgical Oncology, CHU, Lille
| | - S Bonvalot
- Surgery Department, Institut Curie, Paris, France
| |
Collapse
|
20
|
Massard V, Uwer L, Salleron J, Deblock M, Kieffer A, Rios M, Gilson P, Lesur A, Harle A, Merlin JL. Abstract OT1-03-02: CICLADES: Monitoring of ESR1, PIK3CA and AKT1 ctDNA mutations during real-life follow-up of patients with advanced breast cancer treated with endocrine therapy. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-ot1-03-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Activating ESR1 mutations have recently been reported as a key mechanism leading to Aromatase Inhibitor (AI) resistance. ESR1 mutations occur rarely in primary breast cancers. However, in large retrospective studies, ESR1 mutations occurred in up to 39% of Estrogen-Receptor(ER)-positive metastatic breast cancer resistant to AI. Numerous hotspot mutations have been identified, most of them affecting the ligand-binding domain (LBD) and leading to ligand-independent activation of the ER and to resistance to AI.
Phosphatidylinositol 3-kinase (PI3K)/AKT pathway is involved in key Cellular Mechanisms and mutations in PIK3CA and AKT1 are frequently reported in breast cancer.
In this study, we propose to use a capture-based Next Generation Sequencing (NGS) assay and to use the barcoding and polishing features in our analysis pipeline. This assay will be able to detect all mutations on AKT1, PIK3CA, ESR1 and other genes on circulating tumor DNA (ctDNA) extracted from blood samples of patients with breast cancer. We consider that this exon-screening strategy is relevant according to the recent knowledge.
We plan to prospectively include women with advanced breast cancer about to begin standard-of-care first line endocrine therapy (ET). Patients will be required to have histologically confirmed ER-positive, HER2-negative breast cancer and documented loco-regionally advanced or metastatic disease, not amenable to surgery or radiation with curative intent. Patients with endocrine sensitive disease (no prior ET or relapse more than 12 months after completing adjuvant ET) as well as patients with endocrine resistant disease (relapse while on adjuvant ET or within 12 months of completing adjuvant ET) will be enrolled.
ET can be prescribed alone or in combination with a targeted therapy. Nevertheless, we will recruit at least 25% of patients with exclusive ET in the endocrine sensitive group.
Peripheral-blood samples, for analysis of ctDNA, will be obtained from participating patients at pre-specified time points: at start of ET to determine the baseline mutational status of ESR1, PIK3CA, AKT1 and other genes included in a panel of genes of interest in solid tumors, and then, at evaluation of response to therapy until disease progression or end of study.
Patients will be followed for 36 months or until disease progression. Determination of progression will be done per local investigator.
The primary objective is to describe the prevalence of activating ESR1 mutations affecting the LBD, using NGS, from the start of ET to progression or end of study. Secondary objectives include to describe the prevalence of ESR1 mutations affecting other domains, the prevalence of ESR1 mutations in patients with and without endocrine resistance at enrolment and the prevalence of PIK3CA and AKT1 mutations, to demonstrate that ESR1, PIK3CA and AKT1 mutations whatever their times of onset are predictors of progression free survival.
As of June 2018, 8 sites were opened to recruitment and 18 pts were included; the target enrollment is 146. The trial is supported by AstraZeneca.
Citation Format: Massard V, Uwer L, Salleron J, Deblock M, Kieffer A, Rios M, Gilson P, Lesur A, Harle A, Merlin JL. CICLADES: Monitoring of ESR1, PIK3CA and AKT1 ctDNA mutations during real-life follow-up of patients with advanced breast cancer treated with endocrine therapy [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr OT1-03-02.
Collapse
Affiliation(s)
- V Massard
- Institut de Cancerologie de Lorraine, Vandoeuvre les Nancy, France
| | - L Uwer
- Institut de Cancerologie de Lorraine, Vandoeuvre les Nancy, France
| | - J Salleron
- Institut de Cancerologie de Lorraine, Vandoeuvre les Nancy, France
| | - M Deblock
- Institut de Cancerologie de Lorraine, Vandoeuvre les Nancy, France
| | - A Kieffer
- Institut de Cancerologie de Lorraine, Vandoeuvre les Nancy, France
| | - M Rios
- Institut de Cancerologie de Lorraine, Vandoeuvre les Nancy, France
| | - P Gilson
- Institut de Cancerologie de Lorraine, Vandoeuvre les Nancy, France
| | - A Lesur
- Institut de Cancerologie de Lorraine, Vandoeuvre les Nancy, France
| | - A Harle
- Institut de Cancerologie de Lorraine, Vandoeuvre les Nancy, France
| | - JL Merlin
- Institut de Cancerologie de Lorraine, Vandoeuvre les Nancy, France
| |
Collapse
|
21
|
Blay JY, Toulmonde M, Penel N, Mir O, Chevreau C, Anract P, Bompas E, Rios M, Firmin N, Italiano A, Piperno-Neumann S, Kurtz JE, Duffaud F, Rosset P, Bertucci F, Perrin C, Chemin C, Ducimetiere F, Gouin F, Le Cesne A. Natural history of sarcomas and impact of reference centers in the nationwide NETSARC study on 35,784 patients (pts) from 2010 to 2017. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy299] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
22
|
Funes SC, Rios M, Escobar‐Vera J, Kalergis AM. Implications of macrophage polarization in autoimmunity. Immunology 2018; 154:186-195. [PMID: 29455468 PMCID: PMC5980179 DOI: 10.1111/imm.12910] [Citation(s) in RCA: 531] [Impact Index Per Article: 88.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2017] [Revised: 01/31/2018] [Accepted: 02/09/2018] [Indexed: 12/12/2022] Open
Abstract
Macrophages are extremely heterogeneous and plastic cells with an important role not only in physiological conditions, but also during inflammation (both for initiation and resolution). In the early 1990s, two different phenotypes of macrophages were described: one of them called classically activated (or inflammatory) macrophages (M1) and the other alternatively activated (or wound-healing) macrophages (M2). Currently, it is known that functional polarization of macrophages into only two groups is an over-simplified description of macrophage heterogeneity and plasticity; indeed, it is necessary to consider a continuum of functional states. Overall, the current available data indicate that macrophage polarization is a multifactorial process in which a huge number of factors can be involved producing different activation scenarios. Once a macrophage adopts a phenotype, it still retains the ability to continue changing in response to new environmental influences. The reversibility of polarization has a critical therapeutic value, especially in diseases in which an M1/M2 imbalance plays a pathogenic role. In this review, we assess the high plasticity of macrophages and their potential to be exploited to reduce chronic/detrimental inflammation. On the whole, the evidence detailed in this review underscores macrophage polarization as a target of interest for immunotherapy.
Collapse
Affiliation(s)
- Samanta C. Funes
- Facultad de Ciencias BiológicasDepartamento de Genética Molecular y MicrobiologíaMillennium Institute on Immunology and ImmunotherapyPontificia Universidad Católica de ChileSantiagoChile
| | - Mariana Rios
- Facultad de Ciencias BiológicasDepartamento de Genética Molecular y MicrobiologíaMillennium Institute on Immunology and ImmunotherapyPontificia Universidad Católica de ChileSantiagoChile
| | - Jorge Escobar‐Vera
- Facultad de Ciencias de la SaludDepartamento BiomédicoLaboratorio de GenéticaUniversidad de AntofagastaAntofagastaChile
| | - Alexis M. Kalergis
- Facultad de Ciencias BiológicasDepartamento de Genética Molecular y MicrobiologíaMillennium Institute on Immunology and ImmunotherapyPontificia Universidad Católica de ChileSantiagoChile
- Facultad de MedicinaDepartamento de EndocrinologíaEscuela de MedicinaPontificia Universidad Católica de ChileSantiagoChile
| |
Collapse
|
23
|
Martínez LA, Rios M, Droguett K, Villalon MJ. Inflammation Increases the Opening State of Channels in the Epithelium, Releasing High Levels of ATP that Resulted in a Decrease on Mucociliary Transport Velocity in the Airways. FASEB J 2018. [DOI: 10.1096/fasebj.2018.32.1_supplement.744.2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
| | - Mariana Rios
- PhysiologyPontificia Universidad Católica de ChileSantiagoChile
| | - Karla Droguett
- PhysiologyPontificia Universidad Católica de ChileSantiagoChile
| | | |
Collapse
|
24
|
Rios M, Madureira N, Barbosa T, Reis M, Morais L, Ramos A. Genetic, clinical and treatment heterogeneity of three patients with congenital central hypoventilation syndrome. Sleep Med 2017. [DOI: 10.1016/j.sleep.2017.11.818] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
25
|
Blay JY, Soibinet P, Penel N, Bompas E, Duffaud F, Stoeckle E, Mir O, Adam J, Chevreau C, Bonvalot S, Rios M, Kerbrat P, Cupissol D, Anract P, Gouin F, Kurtz JE, Lebbe C, Isambert N, Bertucci F, Toumonde M, Thyss A, Piperno-Neumann S, Dubray-Longeras P, Meeus P, Ducimetière F, Giraud A, Coindre JM, Ray-Coquard I, Italiano A, Le Cesne A. Improved survival using specialized multidisciplinary board in sarcoma patients. Ann Oncol 2017; 28:2852-2859. [PMID: 29117335 PMCID: PMC5834019 DOI: 10.1093/annonc/mdx484] [Citation(s) in RCA: 212] [Impact Index Per Article: 30.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
BACKGROUND Sarcomas are rare but aggressive diseases. Specialized multidisciplinary management is not implemented for all patients in most countries. We investigated the impact of a multidisciplinary tumor board (MDTB) presentation before treatment in a nationwide study over 5 years. PATIENTS AND METHODS NETSARC (netsarc.org) is a network of 26 reference sarcoma centers with specialized MDTB, funded by the French National Cancer Institute to improve the outcome of sarcoma patients. Since 2010, presentation to an MDTB and second pathological review are mandatory for sarcoma patients in France. Patients' characteristics and follow-up are collected in a database regularly monitored and updated. The management and survival of patients presented to these MDTB before versus after initial treatment were analyzed. RESULTS Out of the 12 528 patients aged ≥15 years, with a first diagnosis of soft tissue and visceral sarcoma obtained between 1 January 2010 and 31 December 2014, 5281 (42.2%) and 7247 (57.8%) were presented to the MDTB before and after the initiation of treatment, respectively. The former group had generally worse prognostic characteristics. Presentation to a MDTB before treatment was associated with a better compliance to clinical practice guidelines, for example, biopsy before surgery, imaging, quality of initial surgery, and less reoperations (all P < 0.001). Local relapse-free survival and relapse-free survival were significantly better in patients presented to a MDTB before initiation of treatment, both in univariate and multivariate analysis. CONCLUSION The compliance to clinical practice guidelines and relapse-free survival of sarcoma patients are significantly better when the initial treatment is guided by a pre-therapeutic specialized MDTB.
Collapse
Affiliation(s)
- J-Y Blay
- Department of Medical and Surgical Oncology, Centre Léon Bérard, Lyon; Department of Université Claude Bernard, Lyon.
| | - P Soibinet
- Department of Medical Oncology, Centre J Godinot, Reims
| | - N Penel
- Department of Medical Oncology, Centre Oscar Lambret, Lille
| | - E Bompas
- Department of Medical Oncology, Centre René Gauducheau Nantes, St. Herblain
| | - F Duffaud
- Department of Medical Oncology, La Timone University Hospital, Marseille
| | - E Stoeckle
- Departments of Medical and Surgical Oncology, Institut BergoniéBordeaux
| | - O Mir
- Departments of Medicine and Surgery, Gustave Roussy Cancer Campus, Villejuif
| | - J Adam
- Departments of Medicine and Surgery, Gustave Roussy Cancer Campus, Villejuif
| | - C Chevreau
- Department of Medical Oncology, Institut Claudius Regaud, Toulouse
| | - S Bonvalot
- Departments of Medicine and Surgery, Gustave Roussy Cancer Campus, Villejuif; Departments of Medical and Surgical Oncology, Institut Curie, Paris
| | - M Rios
- Department of Medical Oncology, Centre Alexis Vautrin, Vandoeuvre-lès-Nancy
| | - P Kerbrat
- Department of Medical Oncology, Eugene Marquis Comprehensive Cancer Center, Rennes
| | - D Cupissol
- Department of Medical Oncology, Centre Val d'Aurelle, Montpellier
| | - P Anract
- Department of Orthopedics, Hopital Cochin Saint Vincent de Paul, Paris
| | - F Gouin
- Department of Orthopedics, Centre Hospitalier et Universitaire, Nantes
| | - J-E Kurtz
- Department of Medical Oncology, Hôpitaux Universitaires de Strasbourg, Strasbourg
| | - C Lebbe
- Department of Dermatology and CIC Department, INSERM U976 University Paris Diderot Saint Louis Hospital, Paris
| | - N Isambert
- Department of Medical Oncology, Centre Georges François Leclerc, Dijon
| | - F Bertucci
- Department of Medical Oncology, Institut Paoli Calmettes, Marseille
| | - M Toumonde
- Departments of Medical and Surgical Oncology, Institut BergoniéBordeaux
| | - A Thyss
- Department of Medical Oncology, Centre Antoine-Lacassagne, Nice
| | | | - P Dubray-Longeras
- Department of Medical Oncology, Centre Jean Perrin, Clermont-Ferrand, France
| | - P Meeus
- Department of Medical and Surgical Oncology, Centre Léon Bérard, Lyon; Department of Université Claude Bernard, Lyon
| | - F Ducimetière
- Department of Medical and Surgical Oncology, Centre Léon Bérard, Lyon; Department of Université Claude Bernard, Lyon
| | - A Giraud
- Departments of Medical and Surgical Oncology, Institut BergoniéBordeaux
| | - J-M Coindre
- Departments of Medical and Surgical Oncology, Institut BergoniéBordeaux
| | - I Ray-Coquard
- Department of Medical and Surgical Oncology, Centre Léon Bérard, Lyon; Department of Université Claude Bernard, Lyon
| | - A Italiano
- Departments of Medical and Surgical Oncology, Institut BergoniéBordeaux
| | - A Le Cesne
- Departments of Medicine and Surgery, Gustave Roussy Cancer Campus, Villejuif
| |
Collapse
|
26
|
Blay JY, Stoeckle E, Italiano A, Rochwerger R, Duffaud F, Bonvalot S, Honore C, Decanter G, Maynou C, Anract P, Ferron G, Guillemin F, Gouin F, Rios M, Kurtz J, Meeus P, Coindre J, Ray-Coquard I, Penel N, Le Cesne A. Improved overall and progression free survival after surgery in expert sites for sarcoma patients: A nationwide study of FSG-GETO/NETSARC. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx387.001] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
27
|
Pautier P, Brard C, Floquet A, Gladieff L, Rios M, Piperno-Neumann S, Berton-Rigaud D, Blay JY, Fabbro M, Lotz JP, Vinceneux A, Bertucci F, De La Motte Rouge T, Guillemet C, Genestie C, Duffaud F. A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide and cisplatin (API), followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). Update at 10 years. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx387.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
28
|
Cox D, Blanc E, Romieu G, Rios M, Becuwe C, Jouannaud C, Chaigneau L, Arnedos M, Orfeuvre H, Petit T, Quenel Tueux N, Jacquin JP, Ferrero JM, Abadie Lacourtoisie S, Penault-Llorca F, Segura-Ferlay C, Moullet I, Bachelot T, Pivot X. SToRM: A clinical cohort to identify genetic variability related to metastatic phenotypes. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx440.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
29
|
Italiano A, Adenis A, Blay JY, Duffaud F, Rios M, Bompas E, Bouche O, Pulido M, Le Cesne A. Efficacy and safety of palbociclib in patients with advanced gastrointestinal stromal tumors refractory to imatinib and sunitinib. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx387.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
30
|
Pautier P, Penel N, Ray-Coquard I, Italiano A, Bompas E, Delcambre C, Bay JO, Bertucci F, Delaye J, Chevreau C, Cupissol D, Le Moal LB, Eymard JC, Thyss A, Isambert N, Guillemet C, Rios M, Piperno-Neumann S, Chenuc G, Duffaud F. Results of the LMS03 phase II study evaluating gemcitabine combined with pazopanib as a 2nd-line treatment for metastatic/relapsed leiomyosarcomas (uterine or soft tissue) after failure of anthracycline-based chemotherapy: The UNICANCER SARCOME 11 study. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx440.072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
31
|
Droguett K, Rios M, Carreño DV, Navarrete C, Fuentes C, Villalón M, Barrera NP. An autocrine ATP release mechanism regulates basal ciliary activity in airway epithelium. J Physiol 2017; 595:4755-4767. [PMID: 28422293 PMCID: PMC5509870 DOI: 10.1113/jp273996] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2016] [Accepted: 04/10/2017] [Indexed: 01/07/2023] Open
Abstract
KEY POINTS Extracellular ATP, in association with [Ca2+ ]i regulation, is required to maintain basal ciliary beat frequency. Increasing extracellular ATP levels increases ciliary beating in airway epithelial cells, maintaining a sustained response by inducing the release of additional ATP. Extracellular ATP levels in the millimolar range, previously associated with pathophysiological conditions of the airway epithelium, produce a transient arrest of ciliary activity. The regulation of ciliary beat frequency is dependent on ATP release by hemichannels (connexin/pannexin) and P2X receptor activation, the blockage of which may even stop ciliary movement. The force exerted by cilia, measured by atomic force microscopy, is reduced following extracellular ATP hydrolysis. This result complements the current understanding of the ciliary beating regulatory mechanism, with special relevance to inflammatory diseases of the airway epithelium that affect mucociliary clearance. ABSTRACT Extracellular nucleotides, including ATP, are locally released by the airway epithelium and stimulate ciliary activity in a [Ca2+ ]i -dependent manner after mechanical stimulation of ciliated cells. However, it is unclear whether the ATP released is involved in regulating basal ciliary activity and mediating changes in ciliary activity in response to chemical stimulation. In the present study, we evaluated ciliary beat frequency (CBF) and ciliary beating forces in primary cultures from mouse tracheal epithelium, using videomicroscopy and atomic force microscopy (AFM), respectively. Extracellular ATP levels and [Ca2+ ]i were measured by luminometric and fluorimetric assays, respectively. Uptake of ethidium bromide was measured to evaluate hemichannel functionality. We show that hydrolysis of constitutive extracellular ATP levels with apyrase (50 U ml-1 ) reduced basal CBF by 45% and ciliary force by 67%. The apyrase effect on CBF was potentiated by carbenoxolone, a hemichannel inhibitor, and oxidized ATP, an antagonist used to block P2X7 receptors, which reduced basal CBF by 85%. Additionally, increasing extracellular ATP levels (0.1-100 μm) increased CBF, maintaining a sustained response that was suppressed in the presence of carbenoxolone. We also show that high levels of ATP (1 mm), associated with inflammatory conditions, lowered basal CBF by reducing [Ca2+ ]i and hemichannel functionality. In summary, we provide evidence indicating that airway epithelium ATP release is the molecular autocrine mechanism regulating basal ciliary activity and is also the mediator of the ciliary response to chemical stimulation.
Collapse
Affiliation(s)
- Karla Droguett
- Department of Physiology, Faculty of Biological SciencesPontificia Universidad Católica de ChileSantiagoChile
| | - Mariana Rios
- Department of Physiology, Faculty of Biological SciencesPontificia Universidad Católica de ChileSantiagoChile
| | - Daniela V. Carreño
- Department of Physiology, Faculty of Biological SciencesPontificia Universidad Católica de ChileSantiagoChile
| | - Camilo Navarrete
- Department of Physiology, Faculty of Biological SciencesPontificia Universidad Católica de ChileSantiagoChile
| | - Christian Fuentes
- Department of Physiology, Faculty of Biological SciencesPontificia Universidad Católica de ChileSantiagoChile
| | - Manuel Villalón
- Department of Physiology, Faculty of Biological SciencesPontificia Universidad Católica de ChileSantiagoChile
| | - Nelson P. Barrera
- Department of Physiology, Faculty of Biological SciencesPontificia Universidad Católica de ChileSantiagoChile
| |
Collapse
|
32
|
Pivot X, Pierga JY, Delaloge S, Fumoleau P, Bonnefoi H, Bachelot T, Jouannaud C, Bourgeois H, Rios M, Soulie P, Jacquin J, Lavau-Denes S, Kerbrat P, Faure Mercier C, Pauporte I, Gligorov J, Curtit E, Henriques J, Paget-Bailly S, Romieu G. Superimposable outcomes for sequential and concomitant administration of adjuvant trastuzumab in HER2-positive breast cancer: Results from the SIGNAL/PHARE prospective cohort. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw364.01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
33
|
Curtit E, Pivot X, Henriques J, Paget-Bailly S, Fumoleau P, Rios M, Bonnefoi H, Soulie P, Jouannaud C, Bourgeois H, Pierga JY, Tennevet I, Trillet-Lenoir V, Kerbrat P, Petit T, Bachelot T, Deleuze JF, Pauporte I, Romieu G, Cox D. Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw364.34] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
34
|
Blay JY, Le Cesne A, Penel N, Bompas E, Chevreau C, Duffaud F, Rios M, Kerbrat P, Cupissol D, Anract P, Kurtz JE, Lebbe C, Bertucci F, Piperno-Neumann S, Rosset P, Isambert N, Dubray-Longeras P, Ducimetière F, Coindre JM, Italiano A. The nationwide cohort of 26,883 patients with sarcomas treated in NETSARC reference network between 2010 and 2015 in France: major impact of multidisciplinary board presentation prior to 1st treatment. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw388.03] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
35
|
Agrafiotis AC, Prieto M, Verhaeghe JL, Siat J, Grosdidier G, Rios M. [Treatment of bilateral spontaneous pneumothorax during pazopanib therapy for pulmonary soft tissue sarcoma metastases. What to do when there is so few evidence?]. Rev Pneumol Clin 2016; 72:293-295. [PMID: 27561973 DOI: 10.1016/j.pneumo.2016.05.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/26/2016] [Revised: 05/23/2016] [Accepted: 05/30/2016] [Indexed: 06/06/2023]
Abstract
Soft tissue sarcomas are rare malignant tumors with a great variety of histological types and different response to multimodality treatment. Pazopanib has been recently introduced for the treatment of non-adipocytic metastatic soft tissue sarcomas which are resistant to conventional chemotherapy. Spontaneous pneumothorax is a rare but well recognized complication of this molecule and its treatment is quite challenging. The case reported herein describes the surgical management of a simultaneous bilateral spontaneous pneumothorax in a patient with pulmonary metastases treated with pazopanib. It underlines the fact that the main objective should be the maintenance of the treatment in patients who benefit from it. Close oncologic and surgical collaboration is crucial in order to deal with adverse effects due to the anti-angiogenic action of pazopanib.
Collapse
Affiliation(s)
- A C Agrafiotis
- Service de chirurgie générale, urgences et chirurgie thoracique, centre hospitalo-universitaire de Nancy, 29, avenue du Maréchal-de-Lattre-de-Tassigny, 54035 Nancy, France.
| | - M Prieto
- Service de chirurgie générale, urgences et chirurgie thoracique, centre hospitalo-universitaire de Nancy, 29, avenue du Maréchal-de-Lattre-de-Tassigny, 54035 Nancy, France
| | - J-L Verhaeghe
- Institut de cancérologie de Lorraine, Alexis Vautrin, 6, avenue de Bourgogne, 54500 Vandoeuvre-lès-Nancy, France
| | - J Siat
- Service de chirurgie générale, urgences et chirurgie thoracique, centre hospitalo-universitaire de Nancy, 29, avenue du Maréchal-de-Lattre-de-Tassigny, 54035 Nancy, France
| | - G Grosdidier
- Service de chirurgie générale, urgences et chirurgie thoracique, centre hospitalo-universitaire de Nancy, 29, avenue du Maréchal-de-Lattre-de-Tassigny, 54035 Nancy, France
| | - M Rios
- Institut de cancérologie de Lorraine, Alexis Vautrin, 6, avenue de Bourgogne, 54500 Vandoeuvre-lès-Nancy, France
| |
Collapse
|
36
|
Curtit E, Vincent-Salomon A, Paget-Bailly S, Romieu G, Fumoleau P, Bonnefoi H, Jouannaud C, Petit T, Darut-Jouve A, Trillet-Lenoir V, Tarpin C, Pierga JY, Rios M, Jacquin J, Bachelot T, Cox D, Deleuze JF, Pauporte I, Henriques J, Pivot X. Effects of HER2 immuno-histochemistry expression levels on survival in patients treated by trastuzumab at the adjuvant setting in the SIGNAL/PHARE prospective cohort. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw364.40] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
37
|
Dong M, Fisher C, Añez G, Rios M, Nakhasi HL, Hobson JP, Beanan M, Hockman D, Grigorenko E, Duncan R. Standardized methods to generate mock (spiked) clinical specimens by spiking blood or plasma with cultured pathogens. J Appl Microbiol 2016; 120:1119-29. [PMID: 26835651 DOI: 10.1111/jam.13082] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2015] [Revised: 01/11/2016] [Accepted: 01/20/2016] [Indexed: 11/29/2022]
Abstract
AIMS To demonstrate standardized methods for spiking pathogens into human matrices for evaluation and comparison among diagnostic platforms. METHODS AND RESULTS This study presents detailed methods for spiking bacteria or protozoan parasites into whole blood and virus into plasma. Proper methods must start with a documented, reproducible pathogen source followed by steps that include standardized culture, preparation of cryopreserved aliquots, quantification of the aliquots by molecular methods, production of sufficient numbers of individual specimens and testing of the platform with multiple mock specimens. Results are presented following the described procedures that showed acceptable reproducibility comparing in-house real-time PCR assays to a commercially available multiplex molecular assay. CONCLUSIONS A step by step procedure has been described that can be followed by assay developers who are targeting low prevalence pathogens. SIGNIFICANCE AND IMPACT OF THE STUDY The development of diagnostic platforms for detection of low prevalence pathogens such as biothreat or emerging agents is challenged by the lack of clinical specimens for performance evaluation. This deficit can be overcome using mock clinical specimens made by spiking cultured pathogens into human matrices. To facilitate evaluation and comparison among platforms, standardized methods must be followed in the preparation and application of spiked specimens.
Collapse
Affiliation(s)
- M Dong
- Laboratory of Emerging Pathogens, Division of Emerging and Transfusion Transmitted Diseases, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), Silver Spring, MD, USA
| | - C Fisher
- Laboratory of Emerging Pathogens, Division of Emerging and Transfusion Transmitted Diseases, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), Silver Spring, MD, USA
| | - G Añez
- Laboratory of Emerging Pathogens, Division of Emerging and Transfusion Transmitted Diseases, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), Silver Spring, MD, USA
| | - M Rios
- Laboratory of Emerging Pathogens, Division of Emerging and Transfusion Transmitted Diseases, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), Silver Spring, MD, USA
| | - H L Nakhasi
- Laboratory of Emerging Pathogens, Division of Emerging and Transfusion Transmitted Diseases, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), Silver Spring, MD, USA
| | - J P Hobson
- Office of In Vitro Diagnostics and Radiological Health (OIR), Division of Microbiology Devices, Center for Devices and Radiological Health (CDRH), FDA, Silver Spring, MD, USA
| | - M Beanan
- Office of Biodefense, Research Resources, and Translational Research, Division of Microbiology and Infectious Diseases (DMID), National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, USA
| | - D Hockman
- Diatherix Laboratory, Huntsville, AL, USA
| | | | - R Duncan
- Laboratory of Emerging Pathogens, Division of Emerging and Transfusion Transmitted Diseases, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), Silver Spring, MD, USA
| |
Collapse
|
38
|
Bachelot T, Lavergne E, Romieu G, Rios M, Heudel PE, Roemer-Becuwe C, Jouannaud C, Tredan O, Chaigneau L, Arnedos M, Orfeuvre H, Petit T, Quenel-Tueux N, Jacquin JP, Ferrero JM, Moullet I, Abadie-Lacourtoisie S, Penault-Llorca F, Blanc E, Cox D. Abstract P1-08-06: SToRM: A prospective clinical trial of 1502 metastatic breast cancer (mBC) patients with detail of clinical presentation, molecular subtype, treatment modalities, prognosis and GWAS genotyping. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p1-08-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Due to better molecular classification and new treatment options, epidemiology and prognosis of mBC is rapidly changing. Clinical data extracted from randomized studies are only relevant to specific subpopulations and retrospective studies are prone to selection bias. SToRM is a prospective clinical trial that aims to create a cohort of 1500 mBC patients, with the ultimate goal of identifying germ line polymorphisms associated with prognosis of breast cancer (BC) and response to treatment in the metastatic phase.
Material and methods: Any newly (within 1 year) diagnosed mBC patients were eligible. Whole blood samples were drawn and germline DNA extracted for genetic analysis. Extensive epidemiologic data, disease history from primary diagnosis to metastatic spread, pathological characteristics and ER, PR and HER2 status were collected. Patients are prospectively followed until death. Genotyping using the HumanCoreExome chipset from Illumina is currently underway and will be completed in early summer 2015.
Results: 1502 patients were included from March 2012 to May 2014 from 71 French institutions. Median age at metastatic relapse was 60 years (range 26-93). Median time from primary diagnosis to metastatic relapse was 30 months (range 0-473) with 24% of patients already metastatic at initial diagnosis. 78% of patients were ER+, 18% were HER2+ and only 16% were triple negative. Molecular subtype classification derived from pathological data following St Gallen consensus recommendations is presented below:
n (%)Luminal A like261 (22.2%)Luminal B like HER2 negative476 (40.5%)Luminal B like HER2 positive134 (11.4%)HER2 positive non Luminal (ER-)111 (9.5%)Triple negative193 (16.4%)Missing data327
64% of the patients had received previous adjuvant treatment, among which 81% received adjuvant chemotherapy and 9% trastuzumab.
At metastatic relapse, loco-regional progression, liver, lung and bone metastasis were documented in 301 (20%), 494 (33%), 410 (27%) and 1017 (68%) patients respectively. 313 patients (21%) had bone only metastatic disease. First line treatment included: chemotherapy (71%), endocrine therapy (50%) and anti-HER2 treatments (17%). Survival data will be presented at the meeting.
Conclusion: Despite a theoretically better prognosis and widespread use of adjuvant hormonal treatment, ER+/HER2- breast cancer still account for more than 60% of mBC. The proportion of patients with HER2+ disease (18%) and triple negative disease (16%) is consistent with percentages observed in early BC populations. In comparison with a cohort of "cured", localized cancer, such as the SIGNAL/PHARE study, GWAS analysis will allow for the identification of genetic polymorphisms correlated with treatment resistance. Fundamentally, such variants will provide insight into the molecular mechanisms responsible for host-genetic influence on BC progression. From a clinical perspective, genetic variants that predispose to metastatic disease can serve as stratification variables in future clinical trials, particularly as the development of new treatment options for resistant BC is needed.
Citation Format: Bachelot T, Lavergne E, Romieu G, Rios M, Heudel P-E, Roemer-Becuwe C, Jouannaud C, Tredan O, Chaigneau L, Arnedos M, Orfeuvre H, Petit T, Quenel-Tueux N, Jacquin J-P, Ferrero J-M, Moullet I, Abadie-Lacourtoisie S, Penault-Llorca F, Blanc E, Cox D. SToRM: A prospective clinical trial of 1502 metastatic breast cancer (mBC) patients with detail of clinical presentation, molecular subtype, treatment modalities, prognosis and GWAS genotyping. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P1-08-06.
Collapse
Affiliation(s)
- T Bachelot
- Centre Leon Berard, Lyon cedex 08, France; Institut Régional du Cancer Montpellier (ICM), Montpellier Cedex, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy Cedex, France; Centre d'Oncologie de Gentilly, Nancy, France; Institut Jean Godinot, Reims Cedex, France; CHU de Besançon - Hopital Jean Minjoz, Besançon, France; Gustave Roussy Cancer Campus, Villejuif Cedex, France; Hôpital Fleyriat - Centre Hospitalier de Bourg-en-Bresse, Bourg-en-Bresse Cedex, France; Centre Paul Strauss, Strasbourg Cedex, France; Institut Bergonié, Bordeaux Cedex, France; Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France; Centre Antoine Lacassagne, Nice Cedex 02, France; Clinique de la Sauvegarde, Lyon, France; Institut de Cancérologie de l'Ouest - Paul Papin, Angers Cedex 09, France; Centre Jean Perrin, Clermont-Ferrand Cedex, France
| | - E Lavergne
- Centre Leon Berard, Lyon cedex 08, France; Institut Régional du Cancer Montpellier (ICM), Montpellier Cedex, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy Cedex, France; Centre d'Oncologie de Gentilly, Nancy, France; Institut Jean Godinot, Reims Cedex, France; CHU de Besançon - Hopital Jean Minjoz, Besançon, France; Gustave Roussy Cancer Campus, Villejuif Cedex, France; Hôpital Fleyriat - Centre Hospitalier de Bourg-en-Bresse, Bourg-en-Bresse Cedex, France; Centre Paul Strauss, Strasbourg Cedex, France; Institut Bergonié, Bordeaux Cedex, France; Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France; Centre Antoine Lacassagne, Nice Cedex 02, France; Clinique de la Sauvegarde, Lyon, France; Institut de Cancérologie de l'Ouest - Paul Papin, Angers Cedex 09, France; Centre Jean Perrin, Clermont-Ferrand Cedex, France
| | - G Romieu
- Centre Leon Berard, Lyon cedex 08, France; Institut Régional du Cancer Montpellier (ICM), Montpellier Cedex, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy Cedex, France; Centre d'Oncologie de Gentilly, Nancy, France; Institut Jean Godinot, Reims Cedex, France; CHU de Besançon - Hopital Jean Minjoz, Besançon, France; Gustave Roussy Cancer Campus, Villejuif Cedex, France; Hôpital Fleyriat - Centre Hospitalier de Bourg-en-Bresse, Bourg-en-Bresse Cedex, France; Centre Paul Strauss, Strasbourg Cedex, France; Institut Bergonié, Bordeaux Cedex, France; Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France; Centre Antoine Lacassagne, Nice Cedex 02, France; Clinique de la Sauvegarde, Lyon, France; Institut de Cancérologie de l'Ouest - Paul Papin, Angers Cedex 09, France; Centre Jean Perrin, Clermont-Ferrand Cedex, France
| | - M Rios
- Centre Leon Berard, Lyon cedex 08, France; Institut Régional du Cancer Montpellier (ICM), Montpellier Cedex, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy Cedex, France; Centre d'Oncologie de Gentilly, Nancy, France; Institut Jean Godinot, Reims Cedex, France; CHU de Besançon - Hopital Jean Minjoz, Besançon, France; Gustave Roussy Cancer Campus, Villejuif Cedex, France; Hôpital Fleyriat - Centre Hospitalier de Bourg-en-Bresse, Bourg-en-Bresse Cedex, France; Centre Paul Strauss, Strasbourg Cedex, France; Institut Bergonié, Bordeaux Cedex, France; Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France; Centre Antoine Lacassagne, Nice Cedex 02, France; Clinique de la Sauvegarde, Lyon, France; Institut de Cancérologie de l'Ouest - Paul Papin, Angers Cedex 09, France; Centre Jean Perrin, Clermont-Ferrand Cedex, France
| | - P-E Heudel
- Centre Leon Berard, Lyon cedex 08, France; Institut Régional du Cancer Montpellier (ICM), Montpellier Cedex, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy Cedex, France; Centre d'Oncologie de Gentilly, Nancy, France; Institut Jean Godinot, Reims Cedex, France; CHU de Besançon - Hopital Jean Minjoz, Besançon, France; Gustave Roussy Cancer Campus, Villejuif Cedex, France; Hôpital Fleyriat - Centre Hospitalier de Bourg-en-Bresse, Bourg-en-Bresse Cedex, France; Centre Paul Strauss, Strasbourg Cedex, France; Institut Bergonié, Bordeaux Cedex, France; Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France; Centre Antoine Lacassagne, Nice Cedex 02, France; Clinique de la Sauvegarde, Lyon, France; Institut de Cancérologie de l'Ouest - Paul Papin, Angers Cedex 09, France; Centre Jean Perrin, Clermont-Ferrand Cedex, France
| | - C Roemer-Becuwe
- Centre Leon Berard, Lyon cedex 08, France; Institut Régional du Cancer Montpellier (ICM), Montpellier Cedex, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy Cedex, France; Centre d'Oncologie de Gentilly, Nancy, France; Institut Jean Godinot, Reims Cedex, France; CHU de Besançon - Hopital Jean Minjoz, Besançon, France; Gustave Roussy Cancer Campus, Villejuif Cedex, France; Hôpital Fleyriat - Centre Hospitalier de Bourg-en-Bresse, Bourg-en-Bresse Cedex, France; Centre Paul Strauss, Strasbourg Cedex, France; Institut Bergonié, Bordeaux Cedex, France; Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France; Centre Antoine Lacassagne, Nice Cedex 02, France; Clinique de la Sauvegarde, Lyon, France; Institut de Cancérologie de l'Ouest - Paul Papin, Angers Cedex 09, France; Centre Jean Perrin, Clermont-Ferrand Cedex, France
| | - C Jouannaud
- Centre Leon Berard, Lyon cedex 08, France; Institut Régional du Cancer Montpellier (ICM), Montpellier Cedex, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy Cedex, France; Centre d'Oncologie de Gentilly, Nancy, France; Institut Jean Godinot, Reims Cedex, France; CHU de Besançon - Hopital Jean Minjoz, Besançon, France; Gustave Roussy Cancer Campus, Villejuif Cedex, France; Hôpital Fleyriat - Centre Hospitalier de Bourg-en-Bresse, Bourg-en-Bresse Cedex, France; Centre Paul Strauss, Strasbourg Cedex, France; Institut Bergonié, Bordeaux Cedex, France; Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France; Centre Antoine Lacassagne, Nice Cedex 02, France; Clinique de la Sauvegarde, Lyon, France; Institut de Cancérologie de l'Ouest - Paul Papin, Angers Cedex 09, France; Centre Jean Perrin, Clermont-Ferrand Cedex, France
| | - O Tredan
- Centre Leon Berard, Lyon cedex 08, France; Institut Régional du Cancer Montpellier (ICM), Montpellier Cedex, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy Cedex, France; Centre d'Oncologie de Gentilly, Nancy, France; Institut Jean Godinot, Reims Cedex, France; CHU de Besançon - Hopital Jean Minjoz, Besançon, France; Gustave Roussy Cancer Campus, Villejuif Cedex, France; Hôpital Fleyriat - Centre Hospitalier de Bourg-en-Bresse, Bourg-en-Bresse Cedex, France; Centre Paul Strauss, Strasbourg Cedex, France; Institut Bergonié, Bordeaux Cedex, France; Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France; Centre Antoine Lacassagne, Nice Cedex 02, France; Clinique de la Sauvegarde, Lyon, France; Institut de Cancérologie de l'Ouest - Paul Papin, Angers Cedex 09, France; Centre Jean Perrin, Clermont-Ferrand Cedex, France
| | - L Chaigneau
- Centre Leon Berard, Lyon cedex 08, France; Institut Régional du Cancer Montpellier (ICM), Montpellier Cedex, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy Cedex, France; Centre d'Oncologie de Gentilly, Nancy, France; Institut Jean Godinot, Reims Cedex, France; CHU de Besançon - Hopital Jean Minjoz, Besançon, France; Gustave Roussy Cancer Campus, Villejuif Cedex, France; Hôpital Fleyriat - Centre Hospitalier de Bourg-en-Bresse, Bourg-en-Bresse Cedex, France; Centre Paul Strauss, Strasbourg Cedex, France; Institut Bergonié, Bordeaux Cedex, France; Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France; Centre Antoine Lacassagne, Nice Cedex 02, France; Clinique de la Sauvegarde, Lyon, France; Institut de Cancérologie de l'Ouest - Paul Papin, Angers Cedex 09, France; Centre Jean Perrin, Clermont-Ferrand Cedex, France
| | - M Arnedos
- Centre Leon Berard, Lyon cedex 08, France; Institut Régional du Cancer Montpellier (ICM), Montpellier Cedex, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy Cedex, France; Centre d'Oncologie de Gentilly, Nancy, France; Institut Jean Godinot, Reims Cedex, France; CHU de Besançon - Hopital Jean Minjoz, Besançon, France; Gustave Roussy Cancer Campus, Villejuif Cedex, France; Hôpital Fleyriat - Centre Hospitalier de Bourg-en-Bresse, Bourg-en-Bresse Cedex, France; Centre Paul Strauss, Strasbourg Cedex, France; Institut Bergonié, Bordeaux Cedex, France; Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France; Centre Antoine Lacassagne, Nice Cedex 02, France; Clinique de la Sauvegarde, Lyon, France; Institut de Cancérologie de l'Ouest - Paul Papin, Angers Cedex 09, France; Centre Jean Perrin, Clermont-Ferrand Cedex, France
| | - H Orfeuvre
- Centre Leon Berard, Lyon cedex 08, France; Institut Régional du Cancer Montpellier (ICM), Montpellier Cedex, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy Cedex, France; Centre d'Oncologie de Gentilly, Nancy, France; Institut Jean Godinot, Reims Cedex, France; CHU de Besançon - Hopital Jean Minjoz, Besançon, France; Gustave Roussy Cancer Campus, Villejuif Cedex, France; Hôpital Fleyriat - Centre Hospitalier de Bourg-en-Bresse, Bourg-en-Bresse Cedex, France; Centre Paul Strauss, Strasbourg Cedex, France; Institut Bergonié, Bordeaux Cedex, France; Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France; Centre Antoine Lacassagne, Nice Cedex 02, France; Clinique de la Sauvegarde, Lyon, France; Institut de Cancérologie de l'Ouest - Paul Papin, Angers Cedex 09, France; Centre Jean Perrin, Clermont-Ferrand Cedex, France
| | - T Petit
- Centre Leon Berard, Lyon cedex 08, France; Institut Régional du Cancer Montpellier (ICM), Montpellier Cedex, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy Cedex, France; Centre d'Oncologie de Gentilly, Nancy, France; Institut Jean Godinot, Reims Cedex, France; CHU de Besançon - Hopital Jean Minjoz, Besançon, France; Gustave Roussy Cancer Campus, Villejuif Cedex, France; Hôpital Fleyriat - Centre Hospitalier de Bourg-en-Bresse, Bourg-en-Bresse Cedex, France; Centre Paul Strauss, Strasbourg Cedex, France; Institut Bergonié, Bordeaux Cedex, France; Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France; Centre Antoine Lacassagne, Nice Cedex 02, France; Clinique de la Sauvegarde, Lyon, France; Institut de Cancérologie de l'Ouest - Paul Papin, Angers Cedex 09, France; Centre Jean Perrin, Clermont-Ferrand Cedex, France
| | - N Quenel-Tueux
- Centre Leon Berard, Lyon cedex 08, France; Institut Régional du Cancer Montpellier (ICM), Montpellier Cedex, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy Cedex, France; Centre d'Oncologie de Gentilly, Nancy, France; Institut Jean Godinot, Reims Cedex, France; CHU de Besançon - Hopital Jean Minjoz, Besançon, France; Gustave Roussy Cancer Campus, Villejuif Cedex, France; Hôpital Fleyriat - Centre Hospitalier de Bourg-en-Bresse, Bourg-en-Bresse Cedex, France; Centre Paul Strauss, Strasbourg Cedex, France; Institut Bergonié, Bordeaux Cedex, France; Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France; Centre Antoine Lacassagne, Nice Cedex 02, France; Clinique de la Sauvegarde, Lyon, France; Institut de Cancérologie de l'Ouest - Paul Papin, Angers Cedex 09, France; Centre Jean Perrin, Clermont-Ferrand Cedex, France
| | - J-P Jacquin
- Centre Leon Berard, Lyon cedex 08, France; Institut Régional du Cancer Montpellier (ICM), Montpellier Cedex, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy Cedex, France; Centre d'Oncologie de Gentilly, Nancy, France; Institut Jean Godinot, Reims Cedex, France; CHU de Besançon - Hopital Jean Minjoz, Besançon, France; Gustave Roussy Cancer Campus, Villejuif Cedex, France; Hôpital Fleyriat - Centre Hospitalier de Bourg-en-Bresse, Bourg-en-Bresse Cedex, France; Centre Paul Strauss, Strasbourg Cedex, France; Institut Bergonié, Bordeaux Cedex, France; Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France; Centre Antoine Lacassagne, Nice Cedex 02, France; Clinique de la Sauvegarde, Lyon, France; Institut de Cancérologie de l'Ouest - Paul Papin, Angers Cedex 09, France; Centre Jean Perrin, Clermont-Ferrand Cedex, France
| | - J-M Ferrero
- Centre Leon Berard, Lyon cedex 08, France; Institut Régional du Cancer Montpellier (ICM), Montpellier Cedex, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy Cedex, France; Centre d'Oncologie de Gentilly, Nancy, France; Institut Jean Godinot, Reims Cedex, France; CHU de Besançon - Hopital Jean Minjoz, Besançon, France; Gustave Roussy Cancer Campus, Villejuif Cedex, France; Hôpital Fleyriat - Centre Hospitalier de Bourg-en-Bresse, Bourg-en-Bresse Cedex, France; Centre Paul Strauss, Strasbourg Cedex, France; Institut Bergonié, Bordeaux Cedex, France; Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France; Centre Antoine Lacassagne, Nice Cedex 02, France; Clinique de la Sauvegarde, Lyon, France; Institut de Cancérologie de l'Ouest - Paul Papin, Angers Cedex 09, France; Centre Jean Perrin, Clermont-Ferrand Cedex, France
| | - I Moullet
- Centre Leon Berard, Lyon cedex 08, France; Institut Régional du Cancer Montpellier (ICM), Montpellier Cedex, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy Cedex, France; Centre d'Oncologie de Gentilly, Nancy, France; Institut Jean Godinot, Reims Cedex, France; CHU de Besançon - Hopital Jean Minjoz, Besançon, France; Gustave Roussy Cancer Campus, Villejuif Cedex, France; Hôpital Fleyriat - Centre Hospitalier de Bourg-en-Bresse, Bourg-en-Bresse Cedex, France; Centre Paul Strauss, Strasbourg Cedex, France; Institut Bergonié, Bordeaux Cedex, France; Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France; Centre Antoine Lacassagne, Nice Cedex 02, France; Clinique de la Sauvegarde, Lyon, France; Institut de Cancérologie de l'Ouest - Paul Papin, Angers Cedex 09, France; Centre Jean Perrin, Clermont-Ferrand Cedex, France
| | - S Abadie-Lacourtoisie
- Centre Leon Berard, Lyon cedex 08, France; Institut Régional du Cancer Montpellier (ICM), Montpellier Cedex, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy Cedex, France; Centre d'Oncologie de Gentilly, Nancy, France; Institut Jean Godinot, Reims Cedex, France; CHU de Besançon - Hopital Jean Minjoz, Besançon, France; Gustave Roussy Cancer Campus, Villejuif Cedex, France; Hôpital Fleyriat - Centre Hospitalier de Bourg-en-Bresse, Bourg-en-Bresse Cedex, France; Centre Paul Strauss, Strasbourg Cedex, France; Institut Bergonié, Bordeaux Cedex, France; Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France; Centre Antoine Lacassagne, Nice Cedex 02, France; Clinique de la Sauvegarde, Lyon, France; Institut de Cancérologie de l'Ouest - Paul Papin, Angers Cedex 09, France; Centre Jean Perrin, Clermont-Ferrand Cedex, France
| | - F Penault-Llorca
- Centre Leon Berard, Lyon cedex 08, France; Institut Régional du Cancer Montpellier (ICM), Montpellier Cedex, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy Cedex, France; Centre d'Oncologie de Gentilly, Nancy, France; Institut Jean Godinot, Reims Cedex, France; CHU de Besançon - Hopital Jean Minjoz, Besançon, France; Gustave Roussy Cancer Campus, Villejuif Cedex, France; Hôpital Fleyriat - Centre Hospitalier de Bourg-en-Bresse, Bourg-en-Bresse Cedex, France; Centre Paul Strauss, Strasbourg Cedex, France; Institut Bergonié, Bordeaux Cedex, France; Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France; Centre Antoine Lacassagne, Nice Cedex 02, France; Clinique de la Sauvegarde, Lyon, France; Institut de Cancérologie de l'Ouest - Paul Papin, Angers Cedex 09, France; Centre Jean Perrin, Clermont-Ferrand Cedex, France
| | - E Blanc
- Centre Leon Berard, Lyon cedex 08, France; Institut Régional du Cancer Montpellier (ICM), Montpellier Cedex, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy Cedex, France; Centre d'Oncologie de Gentilly, Nancy, France; Institut Jean Godinot, Reims Cedex, France; CHU de Besançon - Hopital Jean Minjoz, Besançon, France; Gustave Roussy Cancer Campus, Villejuif Cedex, France; Hôpital Fleyriat - Centre Hospitalier de Bourg-en-Bresse, Bourg-en-Bresse Cedex, France; Centre Paul Strauss, Strasbourg Cedex, France; Institut Bergonié, Bordeaux Cedex, France; Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France; Centre Antoine Lacassagne, Nice Cedex 02, France; Clinique de la Sauvegarde, Lyon, France; Institut de Cancérologie de l'Ouest - Paul Papin, Angers Cedex 09, France; Centre Jean Perrin, Clermont-Ferrand Cedex, France
| | - D Cox
- Centre Leon Berard, Lyon cedex 08, France; Institut Régional du Cancer Montpellier (ICM), Montpellier Cedex, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy Cedex, France; Centre d'Oncologie de Gentilly, Nancy, France; Institut Jean Godinot, Reims Cedex, France; CHU de Besançon - Hopital Jean Minjoz, Besançon, France; Gustave Roussy Cancer Campus, Villejuif Cedex, France; Hôpital Fleyriat - Centre Hospitalier de Bourg-en-Bresse, Bourg-en-Bresse Cedex, France; Centre Paul Strauss, Strasbourg Cedex, France; Institut Bergonié, Bordeaux Cedex, France; Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France; Centre Antoine Lacassagne, Nice Cedex 02, France; Clinique de la Sauvegarde, Lyon, France; Institut de Cancérologie de l'Ouest - Paul Papin, Angers Cedex 09, France; Centre Jean Perrin, Clermont-Ferrand Cedex, France
| |
Collapse
|
39
|
|
40
|
Rios M, Carreño DV, Oses C, Barrera N, Kerr B, Villalón M. Low physiological levels of prostaglandins E2 and F2α improve human sperm functions. Reprod Fertil Dev 2016; 28:434-9. [DOI: 10.1071/rd14035] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2014] [Accepted: 06/23/2014] [Indexed: 12/19/2022] Open
Abstract
Prostaglandins (PGs) have been reported to be present in the seminal fluid and cervical mucus, affecting different stages of sperm maturation from spermatogenesis to the acrosome reaction. This study assessed the effects of low physiological PGE2 and PGF2α concentrations on human sperm motility and on the ability of the spermatozoa to bind to the zona pellucida (ZP). Human spermatozoa were isolated from seminal samples with normal concentration and motility parameters and incubated with 1 μM PGE2, 1 μM PGF2α or control solution to determine sperm motility and the ability to bind to human ZP. The effects of both PGs on intracellular calcium levels were determined. Incubation for 2 or 18 h with PGE2 or PGF2α resulted in a significant (P < 0.05) increase in the percentage of spermatozoa with progressive motility. In contrast with PGF2α, PGE2 alone induced an increase in sperm intracellular calcium levels; however, the percentage of sperm bound to the human ZP was doubled for both PGs. These results indicate that incubation of human spermatozoa with low physiological levels of PGE2 or PGF2α increases sperm functions and could improve conditions for assisted reproduction protocols.
Collapse
|
41
|
Torres-Fuentes JL, Rios M, Moreno RD. Involvement of a P2X7 Receptor in the Acrosome Reaction Induced by ATP in Rat Spermatozoa. J Cell Physiol 2015; 230:3068-75. [PMID: 25989529 DOI: 10.1002/jcp.25044] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2014] [Accepted: 05/11/2015] [Indexed: 02/06/2023]
Abstract
The acrosome reaction (AR) is the exocytosis of the acrosomal vesicle in response to different physiological and non-physiological stimuli. Particularly in mammals, the AR is needed for sperm to fuse with the oocyte plasma membrane, and it occurs only in capacitated sperm. Previous evidence in the literature indicates that extracellular ATP induces the AR in capacitated human and bovine spermatozoa, but its receptor has not yet been identified. The aim of this work was to define a putative ATP receptor in rat spermatozoa using pharmacological and biochemical approaches. We found that ATP induced the AR only in capacitated rat spermatozoa, which was inhibited in the presence of two general inhibitors of ATP receptors (P2 receptors), Suramin, and oxidized ATP (oATP), and one inhibitor of P2X receptor (pyridoxalphosphate-6-azophenyl-2',4'-disulfonic acid [PPADS]). In addition, the AR induced by ATP in capacitated rat spermatozoa was inhibited by brilliant blue-G (BB-G) and 17-β-oestradiol, two blockers of P2X7 receptors. Moreover, the ATP analog 2'(3')-O-(4-benzoylbenzoyl) ATP (BzATP) was almost 500 times more potent than ATP to induce the AR, which agrees with the pharmacology of a P2X7 receptor. Here, we show the presence of P2X7 receptor by Western blot and its localization in the tail and acrosome by indirect immunofluorescence. Finally, we quantify the presence of ATP in the rat oviduct during the estrous cycle. We found that the ATP concentration within the lumen of the oviduct is similar to those required to induce acrosome reaction, which agree with its role during in vivo fertilization. Therefore, our results strongly suggest that ATP induces the AR in capacitated rat spermatozoa through a P2X7 receptor, which may be functional during in vivo fertilization.
Collapse
Affiliation(s)
- Jorge L Torres-Fuentes
- Departamento de Fisiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - Mariana Rios
- Departamento de Fisiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - Ricardo D Moreno
- Departamento de Fisiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile
| |
Collapse
|
42
|
Khalifa J, Ouali M, Chaltiel L, Le Guellec S, Le Cesne A, Blay JY, Cousin P, Chaigneau L, Bompas E, Piperno-Neumann S, Bui-Nguyen B, Rios M, Delord JP, Penel N, Chevreau C. Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group. BMC Cancer 2015; 15:700. [PMID: 26472661 PMCID: PMC4608145 DOI: 10.1186/s12885-015-1697-8] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2014] [Accepted: 10/07/2015] [Indexed: 12/25/2022] Open
Abstract
Background Advanced malignant solitary fibrous tumors (SFTs) are rare soft-tissue sarcomas with a poor prognosis. Several treatment options have been reported, but with uncertain rates of efficacy. Our aim is to describe the activity of trabectedin in a retrospective, multi-center French series of patients with SFTs. Methods Patients were mainly identified through the French RetrospectYon database and were treated between January 2008 and May 2013. Trabectedin was administered at an initial dose of 1.5 mg/m2, q3 weeks. The best tumor response was assessed according to the Response Evaluation Criteria In Solid Tumors 1.1. The Kaplan–Meier method was used to estimate median progression-free survival (PFS) and overall survival (OS). The growth-modulation index (GMI) was defined as the ratio between the time to progression with trabectedin (TTPn) and the TTP with the immediately prior line of treatment (TTPn-1). Results Eleven patients treated with trabectedin for advanced SFT were identified. Trabectedin had been used as second-line treatment in 8 patients (72.7 %) and as at least third-line therapy in a further 3 (27.3 %). The best RECIST response was a partial response (PR) in one patient (9.1 %) and stable disease (SD) in eight patients (72.7 %). Disease-control rate (DCR = PR + SD) was 81.8 %. After a median follow-up of 29.2 months, the median PFS was 11.6 months (95 % CI = 2.0; 15.2 months) and the median OS was 22.3 months (95 % CI = 9.1 months; not reached). The median GMI was 1.49 (range: 0.11–4.12). Conclusion Trabectedin is a very promising treatment for advanced SFTs. Further investigations are needed.
Collapse
Affiliation(s)
- J Khalifa
- Department of Medical Oncology, Institut Claudius Regaud/Institut Universitaire du Cancer de Toulouse - Oncopôle, 1, avenue Irène Joliot-Curie, 31059, Toulouse Cedex 9, France.
| | - M Ouali
- Department of Statistics, Institut Claudius Regaud / Institut Universitaire du Cancer de Toulouse - Oncopôle, 1, avenue Irène Joliot-Curie, 31059, Toulouse, France.
| | - L Chaltiel
- Department of Statistics, Institut Claudius Regaud / Institut Universitaire du Cancer de Toulouse - Oncopôle, 1, avenue Irène Joliot-Curie, 31059, Toulouse, France.
| | - S Le Guellec
- Department of Pathology, Institut Claudius Regaud / Institut Universitaire du Cancer de Toulouse - Oncopôle, 1, avenue Irène Joliot-Curie, 31059, Toulouse, France.
| | - A Le Cesne
- Department of Medical Oncology, Institut Gustave Roussy, 114 rue Edouard Vaillant, 94805, Villejuif, France.
| | - J-Y Blay
- Department of Medical Oncology, Centre Léon Bérard, 28 Promenade Léa et Napoléon Bullukian, 69008, Lyon, France.
| | - P Cousin
- Department of Medical Oncology, Centre Léon Bérard, 28 Promenade Léa et Napoléon Bullukian, 69008, Lyon, France.
| | - L Chaigneau
- Department of Medical Oncology, Jean Minjoz University Hospital, 3 Boulevard Alexandre Fleming, 25030, Besançon, France.
| | - E Bompas
- Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Site Hospitalier Nord Boulevard Jacques Monod, 44805, Saint-Herblain, France.
| | - S Piperno-Neumann
- Department of Medical Oncology, Institut Curie, 26 rue d'Ulm, 75248, Paris, France.
| | - B Bui-Nguyen
- Department of Medical Oncology, Institut Bergonié, 229 cours de l'Argonne, 33000, Bordeaux, France.
| | - M Rios
- Department of Medical Oncology, Centre Alexis Vautrin, 6 Avenue de Bourgogne, 54519, Vandœuvre-lès-Nancy, France.
| | - J-P Delord
- Department of Medical Oncology, Institut Claudius Regaud/Institut Universitaire du Cancer de Toulouse - Oncopôle, 1, avenue Irène Joliot-Curie, 31059, Toulouse Cedex 9, France.
| | - N Penel
- Department of Medical Oncology, Centre Oscar Lambret, 3 Rue Frédéric Combemale, 59000, Lille, France.
| | - C Chevreau
- Department of Medical Oncology, Institut Claudius Regaud/Institut Universitaire du Cancer de Toulouse - Oncopôle, 1, avenue Irène Joliot-Curie, 31059, Toulouse Cedex 9, France.
| |
Collapse
|
43
|
Penel N, Coindre J, Cesne AL, Italiano A, Neuville A, Bonvalot S, Terrier P, Ray-Coquard I, Ranchere-Vince D, Robin Y, Isambert N, Chevreau C, Duffaud F, Bertucci F, Rios M, Toulmonde M, Péchoux CL, Guillement C, Courréges J, Blay J. 3400 Management of Desmoid Tumours (DT): A nationwide survey after labeling of 2 expert networks (RRePS and NetSarc). Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(15)30064-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
44
|
Añez G, Jiang Z, Heisey DAR, Kerby S, Rios M. Collaborative study for the characterization of a chikungunya virus RNA reference reagent for use in nucleic acid testing. Vox Sang 2015; 109:312-8. [PMID: 26014282 DOI: 10.1111/vox.12297] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2015] [Revised: 04/14/2015] [Accepted: 04/14/2015] [Indexed: 12/15/2022]
Abstract
BACKGROUND AND OBJECTIVES Infections with the mosquito-borne chikungunya virus (CHIKV) can cause febrile illness or be asymptomatic. Laboratory diagnosis of CHIKV is often made with laboratory-developed nucleic acid amplification technology (NAT) assays because there are no U.S. Food and Drug Administration (FDA)-approved diagnostic or blood screening assays. We aimed to produce a well-characterized CHIKV RNA reference reagent (CHIKV-RR) for use in NAT assays. MATERIALS AND METHODS A CHIKV RNA-RR consisting of cell culture-grown, heat-inactivated CHIKV diluted in human plasma was assessed by 8 laboratories in a collaborative study. The participants were asked to test the CHIKV-RR using their NAT assay(s) by qualitative testing (determination of RNA end-point by testing log and half-log dilutions followed by calculation of estimated NAT-detectable units/ml, after adjustment for the sample volume used for testing), and by quantitative testing, when available. RESULTS Results from the testing showed that the CHIKV-RR had an estimated overall mean of 7.56 log10 detectable units/ml, ranging from 6.2 log10 to 8.6 log10. CONCLUSIONS The Center for Biologics for Evaluation and Research/FDA CHIKV RNA-RR for NAT was established with a concentration of 7.56 log10 detectable units/ml.
Collapse
Affiliation(s)
- G Añez
- Office of Blood Research and Review, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Bethesda, MD, USA
| | - Z Jiang
- Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Bethesda, MD, USA
| | - D A R Heisey
- Office of Blood Research and Review, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Bethesda, MD, USA
| | - S Kerby
- Office of Blood Research and Review, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Bethesda, MD, USA
| | - M Rios
- Office of Blood Research and Review, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Bethesda, MD, USA
| | | |
Collapse
|
45
|
Blay JY, Domont J, Cropet C, Italiano A, Bompas E, Cassier P, Ray-Coquard I, Rios M, Adenis A, Mir O, Bouché O, Bui B, Duffaud F, Bertucci F, Isambert N, Belleville A, Remir E, Gautier J, Le Cesne A, Perol D. A Randomized Multicentre Phase Ii Study of Pazopanib Plus Best Supportive Care (Bsc) Vs Bsc Alone in Metastatic Gastrointestinal Stromal Tumors (Gist) Resistant to Imatinib and Sunitinib. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu438.57] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
46
|
Marina M, Rios M, Torrado P, Busquets A, Angulo-Barroso R. Force-time course parameters and force fatigue model during an intermittent fatigue protocol in motorcycle race riders. Scand J Med Sci Sports 2014; 25:406-16. [PMID: 24730983 DOI: 10.1111/sms.12220] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/20/2014] [Indexed: 11/29/2022]
Abstract
Fatigue in forearm muscles may be critical for motorcycle riders in relation to performance and forearm disorders. Force-time course parameters were examined to better characterize the reduction in the maximal force generating capacity (MVC) during an intermittent fatigue protocol (IFP) specifically designed for motorcycle riders. Also, a mathematical force fatigue model is proposed. Forty motorcyclists (aged 27.6 ± 6.8 years) performed an IFP that simulated the braking gesture and posture of a rider. Fatigue was confirmed by a 40% decrement of the normalized MVC in comparison with basal value. Contraction time increased in comparison with basal condition (P ≤ 0.034). Relaxation kinetics presented two phases: (a) a pre-fatigue phase where half relaxation time (HRTraw ) and normalized (HRTnor ) decreased (P ≤ 0.013) while relaxation rate (RRraw ) remained unchanged; and (b) a fatiguing phase where HRTraw , HRTnor increased and RRraw decreased (P ≤ 0.047). Normalized RRraw (RRnor ) declined progressively (P ≤ 0.016). The proposed nonlinear force fatigue model confirmed a satisfactory adjustment (R(2) = 0.977 ± 0.018). This mathematical expression derived three patterns of force fatigue: three-phase, exponential and linear, representing 70%, 13%, and 17% of the participants, respectively. Overall, these results provided further support to force fatigue theoretical and applied proposals.
Collapse
Affiliation(s)
- M Marina
- INEFC Barcelona, Barcelona, Spain
| | - M Rios
- Facultad Biologia (UB), Barcelona, Spain
| | | | - A Busquets
- School of Health Science, Universitat Pompeu Fabra, Mataro, Spain
| | | |
Collapse
|
47
|
Abstract
Complex interactions between the brain and peripheral tissues mediate the effective control of energy balance and body weight. Hypothalamic and hindbrain neural circuits integrate peripheral signals informing the nutritional status of the animal and in response regulate nutrient intake and energy utilization. Obesity and its many medical complications emerge from the dysregulation of energy homeostasis. Excessive weight gain might also arise from alterations in reward systems of the brain that drive consumption of calorie dense, palatable foods in the absence of an energy requirement. Several neurotrophins, most notably brain-derived neurotrophic factor, have been implicated in the molecular and cellular processes underlying body weight regulation. Here, we review investigations interrogating their roles in energy balance and reward centers of the brain impacting feeding behavior and energy expenditure.
Collapse
Affiliation(s)
- M Rios
- Department of Neuroscience, Tufts University School of Medicine, Boston, MA, 02111, USA,
| |
Collapse
|
48
|
Merlin JL, Lion M, Wong J, Bachelot T, André F, Treilleux I, Loussouarn D, Bonneterre J, Rios M, Diéras V, Jimenez M, Leroux A, Campone M. Abstract P1-08-27: Quantitative analysis of tumor expression of phosphoproteins from PI3-kinase and MAP-kinase signaling pathways as biomarkers of the biological and clinical activity of trastuzumab and everolimus in breast cancer: Unicancer RADHER phase II trial results. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p1-08-27] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: PI3-kinase (PI3K) and MAP kinase (MAPK) are the main signaling pathways implicated in molecular oncogenesis. In breast cancer, inhibition of these signaling pathways has been largely envisaged by means of targeted therapy. Unicancer RADHER study aimed at evaluating the efficacy of adding everolimus (E) to trastuzumab (T) as preoperative therapy for primary HER2+ operable breast cancer patients and to evaluate molecular response biomarkers. We report here the investigation of the expression of phosphoproteins from PI3K and MAPK signaling pathways as predictive biomarkers of clinical and pathological response as well as pharmacodynamic markers of treatment activity.
Methods: 82 eligible patients were randomized to receive T alone (loading dose 4 mg/kg, then 2 mg/kg/week), or T+E (10 mg/day) for a 6-week pre-operative treatment. Clinical response rate (cRR) was determined from OMS criteria with complete and partial responses being considered as “ responders “ and stable and progressive diseases as “ non responders “. Pathological response rate was evaluated according to Sataloff classification, with Ta and Tb being considered as “ responders “ and, Tc and Td as “ non responders “. The expression levels of phosphorylated-AKT (p-AKT), p-GSK3b, p-S6 kinase, p-MEK1, p-ERK1/2, p-P90RSK, p-IGF1R as well as p-P38MAPK were quantitatively assessed using multiplex bead immuno-assay. All patients had baseline needle frozen biopsies taken before initiation of the treatment, at cycle 4 as an option and at surgery. Before being submitted to total protein extraction, all biopsies were validated by a senior pathologist after HE slide examination to ensure a tumor content >50%. 36 pairs associating baseline + surgery tumor specimens and 4 pairs of baseline + cycle 4 biopsies were eligible for protein extraction. Results: No statistically significant relationship was observed between the expression level of any of the phosphoproteins in the initial biopsies and neither the clinical nor the pathological response, overall. After treatment, as compared to the level of expression measured in the initial biopsies, a significant increase of p-GSK3β, p-MEK1, p-ERK1/2, p-P38MAPK was observed in T+E arm and a significant decrease in p-S6 kinase expression in the global patient population. No significant variation was observed in T arm. Additional analysis with immunohistochemistry data is planned and will be presented.
Conclusion: In the present study, measuring phosphoproteins expression showed that combining E with T, altered the regulation of signaling proteins from PI3-Kinase and MAP-kinase pathways. No response predictive biomarker could be identified among the phosphoproteins analyzed tending to show that the clinical and pathological response to T and T+E should be driven by additional mechanisms. As a whole, these results validate the use of multiplex bead immuno-analysis for determination of phosphorylated signaling proteins in clinical needle biopsies from breast cancer specimens and its prospective evaluation as biomarker for the activity of targeted therapies.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P1-08-27.
Collapse
Affiliation(s)
- J-L Merlin
- Institut de Cancérologie de Lorraine, CNRS UMR 7039 CRAN Université de Lorraine, Vandoeuvre les Nancy, France; Institut Curie, Paris, France; Centre Léon Bérard, Lyon, France; Institut Gustave Roussy, Villejuif, France; CHU-Hôpital G&R Laënnec, Nantes, France; Centre Oscar Lambret, Lille, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Institut Curie, Hospital, Paris, France; UNICANCER, Paris, France; Institut de Cancérologie de l'Ouest, Centre de Recherche du Cancer Nantes-Angers :UMR-INSERM U892/CNRS 6299, Université de Nantes, Nantes, France
| | - M Lion
- Institut de Cancérologie de Lorraine, CNRS UMR 7039 CRAN Université de Lorraine, Vandoeuvre les Nancy, France; Institut Curie, Paris, France; Centre Léon Bérard, Lyon, France; Institut Gustave Roussy, Villejuif, France; CHU-Hôpital G&R Laënnec, Nantes, France; Centre Oscar Lambret, Lille, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Institut Curie, Hospital, Paris, France; UNICANCER, Paris, France; Institut de Cancérologie de l'Ouest, Centre de Recherche du Cancer Nantes-Angers :UMR-INSERM U892/CNRS 6299, Université de Nantes, Nantes, France
| | - J Wong
- Institut de Cancérologie de Lorraine, CNRS UMR 7039 CRAN Université de Lorraine, Vandoeuvre les Nancy, France; Institut Curie, Paris, France; Centre Léon Bérard, Lyon, France; Institut Gustave Roussy, Villejuif, France; CHU-Hôpital G&R Laënnec, Nantes, France; Centre Oscar Lambret, Lille, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Institut Curie, Hospital, Paris, France; UNICANCER, Paris, France; Institut de Cancérologie de l'Ouest, Centre de Recherche du Cancer Nantes-Angers :UMR-INSERM U892/CNRS 6299, Université de Nantes, Nantes, France
| | - T Bachelot
- Institut de Cancérologie de Lorraine, CNRS UMR 7039 CRAN Université de Lorraine, Vandoeuvre les Nancy, France; Institut Curie, Paris, France; Centre Léon Bérard, Lyon, France; Institut Gustave Roussy, Villejuif, France; CHU-Hôpital G&R Laënnec, Nantes, France; Centre Oscar Lambret, Lille, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Institut Curie, Hospital, Paris, France; UNICANCER, Paris, France; Institut de Cancérologie de l'Ouest, Centre de Recherche du Cancer Nantes-Angers :UMR-INSERM U892/CNRS 6299, Université de Nantes, Nantes, France
| | - F André
- Institut de Cancérologie de Lorraine, CNRS UMR 7039 CRAN Université de Lorraine, Vandoeuvre les Nancy, France; Institut Curie, Paris, France; Centre Léon Bérard, Lyon, France; Institut Gustave Roussy, Villejuif, France; CHU-Hôpital G&R Laënnec, Nantes, France; Centre Oscar Lambret, Lille, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Institut Curie, Hospital, Paris, France; UNICANCER, Paris, France; Institut de Cancérologie de l'Ouest, Centre de Recherche du Cancer Nantes-Angers :UMR-INSERM U892/CNRS 6299, Université de Nantes, Nantes, France
| | - I Treilleux
- Institut de Cancérologie de Lorraine, CNRS UMR 7039 CRAN Université de Lorraine, Vandoeuvre les Nancy, France; Institut Curie, Paris, France; Centre Léon Bérard, Lyon, France; Institut Gustave Roussy, Villejuif, France; CHU-Hôpital G&R Laënnec, Nantes, France; Centre Oscar Lambret, Lille, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Institut Curie, Hospital, Paris, France; UNICANCER, Paris, France; Institut de Cancérologie de l'Ouest, Centre de Recherche du Cancer Nantes-Angers :UMR-INSERM U892/CNRS 6299, Université de Nantes, Nantes, France
| | - D Loussouarn
- Institut de Cancérologie de Lorraine, CNRS UMR 7039 CRAN Université de Lorraine, Vandoeuvre les Nancy, France; Institut Curie, Paris, France; Centre Léon Bérard, Lyon, France; Institut Gustave Roussy, Villejuif, France; CHU-Hôpital G&R Laënnec, Nantes, France; Centre Oscar Lambret, Lille, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Institut Curie, Hospital, Paris, France; UNICANCER, Paris, France; Institut de Cancérologie de l'Ouest, Centre de Recherche du Cancer Nantes-Angers :UMR-INSERM U892/CNRS 6299, Université de Nantes, Nantes, France
| | - J Bonneterre
- Institut de Cancérologie de Lorraine, CNRS UMR 7039 CRAN Université de Lorraine, Vandoeuvre les Nancy, France; Institut Curie, Paris, France; Centre Léon Bérard, Lyon, France; Institut Gustave Roussy, Villejuif, France; CHU-Hôpital G&R Laënnec, Nantes, France; Centre Oscar Lambret, Lille, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Institut Curie, Hospital, Paris, France; UNICANCER, Paris, France; Institut de Cancérologie de l'Ouest, Centre de Recherche du Cancer Nantes-Angers :UMR-INSERM U892/CNRS 6299, Université de Nantes, Nantes, France
| | - M Rios
- Institut de Cancérologie de Lorraine, CNRS UMR 7039 CRAN Université de Lorraine, Vandoeuvre les Nancy, France; Institut Curie, Paris, France; Centre Léon Bérard, Lyon, France; Institut Gustave Roussy, Villejuif, France; CHU-Hôpital G&R Laënnec, Nantes, France; Centre Oscar Lambret, Lille, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Institut Curie, Hospital, Paris, France; UNICANCER, Paris, France; Institut de Cancérologie de l'Ouest, Centre de Recherche du Cancer Nantes-Angers :UMR-INSERM U892/CNRS 6299, Université de Nantes, Nantes, France
| | - V Diéras
- Institut de Cancérologie de Lorraine, CNRS UMR 7039 CRAN Université de Lorraine, Vandoeuvre les Nancy, France; Institut Curie, Paris, France; Centre Léon Bérard, Lyon, France; Institut Gustave Roussy, Villejuif, France; CHU-Hôpital G&R Laënnec, Nantes, France; Centre Oscar Lambret, Lille, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Institut Curie, Hospital, Paris, France; UNICANCER, Paris, France; Institut de Cancérologie de l'Ouest, Centre de Recherche du Cancer Nantes-Angers :UMR-INSERM U892/CNRS 6299, Université de Nantes, Nantes, France
| | - M Jimenez
- Institut de Cancérologie de Lorraine, CNRS UMR 7039 CRAN Université de Lorraine, Vandoeuvre les Nancy, France; Institut Curie, Paris, France; Centre Léon Bérard, Lyon, France; Institut Gustave Roussy, Villejuif, France; CHU-Hôpital G&R Laënnec, Nantes, France; Centre Oscar Lambret, Lille, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Institut Curie, Hospital, Paris, France; UNICANCER, Paris, France; Institut de Cancérologie de l'Ouest, Centre de Recherche du Cancer Nantes-Angers :UMR-INSERM U892/CNRS 6299, Université de Nantes, Nantes, France
| | - A Leroux
- Institut de Cancérologie de Lorraine, CNRS UMR 7039 CRAN Université de Lorraine, Vandoeuvre les Nancy, France; Institut Curie, Paris, France; Centre Léon Bérard, Lyon, France; Institut Gustave Roussy, Villejuif, France; CHU-Hôpital G&R Laënnec, Nantes, France; Centre Oscar Lambret, Lille, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Institut Curie, Hospital, Paris, France; UNICANCER, Paris, France; Institut de Cancérologie de l'Ouest, Centre de Recherche du Cancer Nantes-Angers :UMR-INSERM U892/CNRS 6299, Université de Nantes, Nantes, France
| | - M Campone
- Institut de Cancérologie de Lorraine, CNRS UMR 7039 CRAN Université de Lorraine, Vandoeuvre les Nancy, France; Institut Curie, Paris, France; Centre Léon Bérard, Lyon, France; Institut Gustave Roussy, Villejuif, France; CHU-Hôpital G&R Laënnec, Nantes, France; Centre Oscar Lambret, Lille, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Institut Curie, Hospital, Paris, France; UNICANCER, Paris, France; Institut de Cancérologie de l'Ouest, Centre de Recherche du Cancer Nantes-Angers :UMR-INSERM U892/CNRS 6299, Université de Nantes, Nantes, France
| |
Collapse
|
49
|
Campone M, Bachelot T, Paoletti X, Merlin J, Delaloge S, Loussouarn D, Bonneterre J, Jimenez M, Rios M, Treilleux I. Predictive Value of AKT/MTOR Pathway Immunohistochemical (IHC) Biomarkers for Response to Preoperative Trastuzumab (T) vs Trastuzumab + Everolimus (T + E) in Patients (PTS) with Early Breast Cancer (BC): Unicancer Radher Trial Results. Ann Oncol 2013. [DOI: 10.1093/annonc/mdt084.4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
50
|
Carreno DV, Llados C, Rios M, Cohen N, Villalon M. LPS increase of ciliary beat frequency in respiratory ciliated cells. FASEB J 2013. [DOI: 10.1096/fasebj.27.1_supplement.1215.1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
| | - Carmen Llados
- PhysiologyPontificia Universidad Catolica de ChileSantiagoChile
| | - Mariana Rios
- PhysiologyPontificia Universidad Catolica de ChileSantiagoChile
| | - Noam Cohen
- Department of Otorhinolaryngology, Head and Neck Surgery.Hospital of the University of PennsylvaniPhiladelphiaPA
| | - Manuel Villalon
- PhysiologyPontificia Universidad Catolica de ChileSantiagoChile
| |
Collapse
|